SUBJECT INDEX 1967

This index covers all reading matter in Volume 16 of DIABETES. Entries marked with an asterisk (*) indicate material that appeared in the Abstracts only. The Author Index appears on page 21.

A

ABDOMEN
surgery and glucose tolerance, *136

ACANTHOSIS NIGRICANS, *358

ACETATE
antilipolytic actions, *508
and glucose and palmitate metabolism, *202

ACETATE-1-C-14
metabolism, *202

ACETEST TABLETS, 83

ACETOHEXAMIDE
and hypoglycemic stupor, *66
metabolism, blood levels, and excretion rates, 118-126
and pancreatic islet cell function, *206

ACETONE
response to triglycerides, *134

ACETOPHENETIDIN
sensitivity and amino acid disorders, *356

ACID ALCOHOL
and plasma insulin activity, 418

ACIDOSIS, DIABETIC
and lipemia, *534

ACIDOSIS, METABOLIC
and sodium bicarbonate and sodium lactate effect on muscles, *135

ACIDS
ethacrynic
and carbohydrate metabolism, *602-603
ethanol extracts
and insulin-like activity, 289-300
linoleic
in infant nutrition, 492, 501
oleic
absorption, 459
sialic
and prediabetes, 615
uric
in glycogen storage disease, *276

ACROMEGALY
and dexamethasone, *204

ACTH. *See* Adrenocorticotrophic hormone

3,5-ADENOSINE-MONOPHOSPHATE
and glycogenolytic effect, *275
and insulin release, 449-453

ADRENAL GLANDS
function
and malnutrition, 155
and hepatic glutamic dehydrogenase, *278
and insulin distribution, 405-407
and insulin inhibition, *523
stimulation
and insulin, *357

ADRENALECTOMY
and adipose-tissue extracts, *886
and electric shock stress, 325-330
and insulin tolerance, *746-747

ADRENALIN
and adipose tissue metabolites, *65
and insulin secretion, *207

ADRENERGIC BLOCKING AGENTS
and epinephrine-induced insulin suppression, *513
glucagon, *357
and isoproterenol infusion, 152-153
and lipolysis, 584-586
and vagal stimulation, 447-448

ADRENERGIC STIMULATING AGENTS, 150-154

ADRENOCORTICOTROPHIC HORMONE
and fat cell metabolism, *743
and glucose uptake, 30-31
and insulin release, 377, 449-453, *815
and plasma proteins, *207
release
and lipolytic hormones, *67
and prediabetes, 615

AFRICANS
malnutrition and glucose tolerance in, 96

AGE
and arginine response, 268
and carbohydrate metabolism, *435
of children in glucose tolerance tests, 11, 12
and diabetes, 858, 861
in mental hospital, 725
and diabetic amyotrophy, 189
and fatty acids of adipose tissue, *674
and glucose tolerance, 173-174
and hyperglycemia, 21, 233
and hyperlipidemia and hyperglycemia, *506
and insulin-like activity, 700
and insulin response, 469
and periodontal disease in diabetes, 339
and response to Valsalva maneuver, 463
and spontaneous lesions in rats, 110
of subjects in glucose tolerance and tolbutamide response comparison study, 15
and substrate regulation in fasting, 576, 578
and tolbutamide response test, 161-169
and triamcinolone provocative tests, 58, 59, 60
and vascular disease, 826

ALBUMIN
and C-14 incorporation, 755
and insulin
antagonism, 289-300, 386-393
inhibition, *275
and synalbumin antagonist, *890

ALCOHOL
antilipolytic actions, *508
and hypoglycemia, *205-206

ALCOHOLISM
and lipid metabolism, 39

ALDOSTERONE
biosynthesis study, *205

ALLERGIES
to milk, 376, 486, *602

ALLOXAN
diabetogenic effect
and epinephrine, 130-131
and insulin degradation, *513
and pancreas beta-cells, 242, *815
and pancreas study, 83-88
and placental insulin transfer, *528-529
and thyroid hormone secretion, *356-357

ALLOXAN DIABETES
and adipose tissue metabolism, *65, *204
and B-glucuronidase activities, *134
and citrate metabolism, *743
compared with streptozotocin-induced diabetes, 54

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70	May, 283-368	September, 615-680
February, 71-140	June, 369-442	October, 681-752
March, 141-210	July, 443-544	November, 753-824
April, 211-282	August, 545-614	December, 825-896

effect on mouse pancreas, 83-88
effect on rat placenta, 227-231
and electric shock stress, 319-323
and liver vitamin A, 706
quantitative study, *747
and testosterone, *741
and tranylcypromine, 810-811
and triglyceride metabolism, 90-95
and zinc metabolism, *601-602

AMERICAN DIABETES ASSOCIATION
annual meetings
Twenty-eighth, 441, 541, 613, 678, 749, 821-822, 893-894
Twenty-seventh, 68, 138, 208, 280-281, 362-367, 541, 604-613, 628
awards
Banting Medals, 281, 363, 604
Lilly, 542, 614, 679-680, 750-751, 822
books on diabetes for patients, 542-543
Christmas Gift Opportunities, 822-823
Committees of the American Diabetes Association for the Organizational Year, 1967-1968, 894
Committee on Affiliate Associations, 895
Committee on Bequests, 895
Committee on Camps, 895
Committee on Charles H. Best Birthplace, 895
Committee on Emergency Medical Care, 895
Committee on Employment and Insurance, 895
Committee on Food and Nutrition, 894
Committee on Functions and Structure, 895
Committee on Information for Diabetics, 895
Committee on Policies, 895
Committee on Professional Education, 894
Committee on Public Education and Detection, 895
Committee on Research, 895
Committee on Scientific Awards, 894
Committee on Scientific Programs, 894
Committee of State Coordinators, 895
Committee on Statistics, 894
Committee on the Use of Therapeutic Agents, 894-895
"Diabetes in Review: Clinical Conference 1968," 367
Diabetes and Obesity Conference, 140
Diabetes Week, 441, 543
Diabetologia subscription rates, 282
Executive Committee, 894
films, 139, 543, 823, 896
FORECAST
"Drugs that Raise or Lower Blood Sugar," 281
"Eye Disturbances in Diabetes," 69
"Vascular Disorders in Diabetes," 543
International Diabetes Federation Sixth Congress, 210, 281, 441
International Symposium on Lipid Metabolism, 896
Joseph H. Crampton Memorial Fund, 60
Journal
binders, 209
index, 69
necrology, 70-71, 140, 210, 282, 368, 544, 752, 896
new members, 69, 139, 209-210, 367-377, 442, 543, 680, 823
news of Affiliate Associations, 69-70, 210, 281, 368, 544, 614, 680, 752
news notes, 70, 139-140, 210, 281, 368, 442, 544, 680, 752, 823, 896
Nominating Committee, 894
obituaries
Crampton, Joseph H., 64
Guest, George Martin, 670
Mulholland, Henry B., 132-133
Warvel, John H., Sr., 739
personals, 70, 210, 282, 368, 442, 544, 896
postgraduate courses, 209, 281, 282, 367, 441, 541, 613, 676, 749, 821, 893
Research Contest winner, 751
Research and Development Award Program, 541-542, 613
Research and Essay Contests, 68-69, 138-139, 751-752
research support program, 679, 750
research symposium, 281, 367, 441, 541, 749-750

AMINO ACIDS
in canned food, 461
disorders, *356
and gluconeogenesis, *536
and growth hormone, *207
high-resolution screening, 417
incorporation into protein, *203
and insulin, *356, *359, 377, *510-511, 691-692
metabolism
and free fatty acids and insulin, 753-763
and sugar absorption, *135
and zinc glucagon, *517-518

AMPUTATION, *136-137
and insulin application, *67
prevention, *66

AMYOTROPHY, DIABETIC, 181-189

ANGIOPATHY
of "chemical" asymptomatic diabetes, *526
and diabetes, 825-837
fluorescein
and diabetic retinopathy, 1-10
and glomerular ultrastructure, 628
and mitochondria, *742

ANHIDROSIS, *277

ANTAGONISTS. *See* Antibodies to insulin; Synalbumin antagonist

ANTIBIOTICS
and induced diabetes, 51-60

ANTIBODIES
to insulin, *820, 829-830
and insulin source, *276

ANTIGLUCAGON
and carbohydrate and lipid metabolism, *65

ARGININE
and growth hormone deficiency, 478-481, *603
and hyperglycemia, 268-271
-initiated hormonal release
and cortisone pretreatment, *530

ARTERIES
fluorescein studies and retinopathy, 1-10
and insulin-like activity, *745
umbilical
and insulin levels, *819

ARTERIOGRAPHY
of metastatic islet cell tumors, 598-599

ARTERIOSCLEROSIS
and diabetes, 826
and pituitary ablation, 636-642

ASPARTATE
and sugar transport, *135

ATHEROSCLEROSIS
and glucose tolerance, 171-174
and glucose intolerance, *277-278
hypercholesterolemic, *521
in squirrel monkeys, 400-401

ATROPINE
and insulin and glucose, 446

AUTOANALYZER FERRICYANIDE METHOD, 233

AUTOANALYZER TEST, 62, 291, 313

B

BASEMENT MEMBRANE
capillary
in juvenile diabetes, *675
in diabetic rat placenta, 229
studies, *818

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70	May, 283-368	September, 615-680
February, 71-140	June, 369-442	October, 681-752
March, 141-210	July, 443-544	November, 753-824
April, 211-282	August, 545-614	December, 825-896

thickening, *205
in dermal capillaries, 194-196
and diabetes, 628-634
and pituitary ablation, 636-642

BENZOTHIADIAZINE
and glucose tolerance, *435

BIGUANIDES
and diabetic obesity, 600
and liver metabolism, *817-818
metabolic effects of, *515-516, *818

BISHYDROXYCOUMARIN, *136

BLADDER
in diabetes, 331-334
and latent diabetes, *534-535

BLOOD
acetohexamide levels, 120-122
dyscrasias
and carbohydrate metabolism, *135
flow
retinal, 6-7
and vagal stimulation, 447
flow rates
and glucose tolerance tests, *436
groups
and diabetes, *355
hemoglobin and red blood cells
and low-protein diet study, 100
insulin
and leucine, *135
and insulin infusion, *820
samples
and atherogenic diet, 72
in glucose tolerance test study, 12
in glucose tolerance and free fatty acid study, 175
and infants of diabetic mothers, 307
in insulin secretion study, 142
in insulin-like activity study, 696-697
in perinatal period, *359
of squirrel monkey, 396
sampling technics
in glucose tolerance tests, 219-226
serum
in diabetes, 348
nonsuppressible insulin-like activity, *66
of sheep fetuses
metabolism study, *133

BLOOD GLUCOSE, *See also* Blood sugar
and anoxia, 387
and arginine, 268-269
and chlorpropamide or phenformin, 487
and cyclic 3′,5′-AMP infusion, *275
and diabetic instability, *535
and fasting
and lipoprotein lipase activity, 239-240
and glucagon, *357
homeostasis
and kidney, *507
and infants of diabetic mothers, 307-309
insulin-induced adrenocortical stimulation, *357
monitoring, *528-529
and oral contraceptives, *137, 590-594
and perinatal period, *359
and pituitary hormones, *359
regulation
and hypothalamus, *443
and streptozotocin injections, 52
tests
Dextrostix, *360
in alloxan diabetic mice, 83, 87
and tolbutamide treatment
in juvenile diabetics, 216-218

BLOOD PRESSURE
in diabetic amyotrophy patient, 181, 182
and epinephrine, *505
intraocular
and diabetic retinopathy, *890

BLOOD SUGAR. *See also* Blood glucose
and acetohexamide ingestion, *66
of alloxanized rabbits, 243
and alloxanized rats
and electric shock stress, 319-323
and diabetes, *440
and diabetes prevalence study, 859
diagnostic levels of, 225-226
and electric shock stress, 319-323, 325-330
fasting
and phenethylbiguanide, 302-304
and glucose uptake, *741-742
and glycosuria, 502-503
and growth hormone, *358
in hypopituitary diabetics, *746
and insulin response, *887
measurement
and diabetes detection, 219-226
in postgastrectomy patients, *67
and prediabetes, 621
and siblings of diabetic children, 157
and sugar intake, 63
and sulphonylurea-induced hypoglycemia, *601
tests
and diabetogenic effect of epinephrine, 130-131
and tolbutamide-dicoumarol treatment, 212-213
and tumors
and hypoglycemia, 416

BLOOD VESSELS
capillaries
and diabetic microangiopathy, 595-597
in juvenile diabetes, *675
of South Africans, 191-196
and diabetic retinopathy, 1-10

BODY
feet
program for care of, *66
lower extremities
and diabetic amyotrophy, 181
and diabetic foot lesions, *815
and management of vascular disease, *67

BONES
and diabetic osteopathy, *438-439

BOOK REVIEWS
Clinical Pathology of the Serum Electrolytes, edited by F. William Sunderman and F. William Sunderman, Jr., 671
Diabetes for Diabetics, by George F. Schmitt, 671
Diabetes Mellitus: Diagnosis and Treatment, edited by George J. Hamwi, and T. S. Danowski, 752, 896
Diabetes Mellitus: Report of a WHO Expert Committee, 354
Genetics in Medicine, by J. S. Thompson and M. W. Thompson, 354
D-Glucose und Verwandte Verbindungen in Medizin und Biologie (D-Glucose and Related Compounds in Medicine and Biology, edited by H. Bartelheimer and W. Thorn, 740
The New Way to Live With Diabetes: A Complete Guide, by Charles Weller and Brian Richard Boylan, 434-435
On the Nature and Treatment of Diabetes, edited by Bernard S. Leibel and Gerald A. Wrenshall, 354
The Pathology of Diabetes Mellitus, by Shields Warren, Philip M. LeCompte, and Merle A. Legg, 812
Vascular Complications of Diabetes Mellitus—With Special Emphasis on Microangiopathy of the Eye, edited by Samuel J. Kimura and Wayne M. Caygill, 740

BRAIN
hexokinase, *816
insulin
in insulin distribution study, 405-407

C

CAFFEINE
and glucose uptake, *355

CALCIUM
and insulin secretion, 357-358

CALORIES
intake study, 34
and malnutrition therapy, 149, 155

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70
February, 71-140
March, 141-210
April, 211-282
May, 283-368
June, 369-442
July, 443-544
August, 545-614
September, 615-630
October, 681-752
November, 753-824
December, 825-896

protein-deficient
and glucose tolerance, 96-106

CARBOHYDRATES
dietary
and diabetes incidence, 62-63
and glucose tolerance, 96, *888
and glucose tolerance curve, *134
and pre-lesion biochemical changes, *748
and free fatty acids and insulin, 578
homeostasis
in juvenile diabetes, *504
and insulin release, *232
intolerance
in postgastrectomy patients, *67
metabolism
and dietary triglycerides clearance, 90
and oral contraceptives, *361
tolerance
and age, *435
tolerance tests
study of, *202

CARBON
flow in rat heart and adipose tissue, *888

CARBON DIOXIDE
and glucose metabolism, *890

CARBOXYPEPTIDASE
and insulin, *206

CARBUTAMIDE
and glycodiazine, *204
and metabolism, *355-356

CARCINOMA
alpha-cell
glucagon-secreting, *135
and diabetes, *521

CARDIOVASCULAR DISEASE. *See also* Heart disease
and diabetes and cholesterol, 71-81
ischemic
and glucose tolerance and tolbutamide response, 15-17
in squirrel monkey, 400

CARDIOVASCULAR SYSTEM
responses
in diabetes, 462-465

CASE REPORTS
abdominal surgery and glucose tolerance, *136
carbohydrate metabolism and blood dyscrasias, *135
congenital absence of beta-lipoproteins, 474, 477
diabetes and mumps, *438
diabetic amyotrophy, 181-182
diabetic retinopathy, *137
glucagon-secreting alpha-cell carcinoma of pancreas, *135
glucose tolerance and ovulatory suppressants, *136
glycogenosis, *891
hyperglycinemia and urinary ketones, *135-136
hypoglycemia and propranolol, *438
hypoglycemic shock during sodium tolbutamide test, *539
hyponatremia and pituitary stalk section, *524
insulin resistance and psychotherapy, *536
islet cell adenoma in childhood, *436
juvenile diabetes, *887
latent diabetes in relatives of diabetics, *137
leucine-sensitive hypoglycemia, *135
lipoatrophic diabetes and mental illness in three siblings, 708-713
lipodystrophy, 715-716
metastatic islet cell tumors in liver, 598-599
oral contraceptives and plasma insulin and blood glucose levels, *137
renal papillary necrosis, 664-665
steatorrhea and diabetes, 459
tolazamide-induced hypoglycemia, 352-353

CATARACTS, *278
and rats on atherogenic diet, 74

CATECHOLAMINES
and glucagon, *357
and juvenile diabetes, *504-505

CELIAC DISEASE, *602

CEREBROSPINAL FLUID
and glucose consumption, *887

CHILDREN
diabetic
and vascular disorders, *889
and tolbutamide, 215-218
of diabetic mothers
and insulin levels, *819
of diabetic parents
and family history study, 41-49
and triamcinolone provocative tests, 57-60
diabetic syndrome, *744
and glucose ingestion
and electrocardiograms, *889
and growth hormone
and nitrogen retention, *887
and hypoglycemia, *816
and diabetes, *205
and glycogenosis, *891
and pancreatectomy, *438
hypopituitary
and prolactin, *202
and hypothyroidism and hypopituitarism
and glucose-6-phosphate dehydrogenase, *603
idiopathic hypoglycemia
management, *136
and islet cell adenoma, *436
malnourished
and carbohydrate absorption, *742
normal
and glucose tolerance tests, 11-14
siblings of diabetics
and glucose tolerance tests, 156-160
vitamin E deficiency
and steatorrhea, 376

CHINESE HAMSTERS
and diabetes, *673, *744, *745, *817
and glomerulopathy, *816
and insulin secretion, *745-746

CHLORPROPAMIDE
and diabetes, *744
and diabetic pregnancy, 60-61
and glycodiazine, *204
and serum glucose and immunoreactive insulin, 487

CHOLESTEROL
and diabetes and cardiovascular lesions, 71-81
and diabetic obesity, *601
and pancreatectomized - sympathectomized dogs, 262

CHROMATOGRAPHY
gas
and induced ketogenesis, *134
gas-liquid
of free fatty acids, 177
paper
compared with gel filtration, *530
thin-layer
of free fatty acids, 175-176

CHYLE
in triglyceride metabolism study, 90-95

CHYLOMICRON
clearing
and glucose and insulin deprivation, 90

CITRATE
and lipid metabolism, *509
metabolism
and diabetes, *743

CLINITEST, 557-559

CO-57-CYANOCOBALAMIN, 264-267

COMA
and drug ingestion, *66
hyperglycemic, 191

CONGENTIAL DEFECTS
absence of beta-lipoproteins, 474, 477
and insulin antagonism, *360
and maternal carbohydrate disorders, 127-129
and maternal diabetes, 61, 308
and maternal prediabetes, *133-134

CORI CYCLE, *889

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70
February, 71-140
March, 141-210
April, 211-282
May, 283-368
June, 369-442
July, 443-544
August, 545-614
September, 615-680
October, 681-752
November, 753-824
December, 825-896

CORONARY DISEASE. *See* Cardiovascular disease, Heart disease

CORTICOIDS
in liver, *531
and serum insulin, glucose, protein and free fatty acid responses, *520

CORTICOSTEROIDS
and hypoglycemia, *135
and intraocular pressure, *355

CORTISOL, *435
binding
and plasma transcortin, *888
and glucose utilization in sheep, *134
and insulin tolerance, *746-747
and plasma amino nitrogen, *817
and plasma insulin, 566-570
production rates
and neonatal hypoglycemia, *438

CORTISONE
-glucose tolerance test, *505
and early latent diabetes, *137
and glycosuria and insulin, 18-20
and hormone release, *530
-induced diabetes
and growth hormone, *276
and lipoatrophic diabetes, 708
tests, 59-60

CRYPTORCHIDISM, *744

CYSTEINE
and plasma insulin activity
and glutathione, 2, 9, 13, 418

D

2-DEOXYGLUCOSE
and insulin release, *277, 379-384, *436
and lipolysis, *888

DESOXYCORTICOSTERONE ACETATE
and carbohydrate and lipid metabolism, 312-317

DEXAMETHASONE
and gluconeogenesis, *522
and glucose and tolbutamide response, *204

DEXTRAN SULFATE
and plasma lipoprotein lipase activity, 238

DIABETES INSIPIDUS
and diguanides, *66

DIABETES MELLITUS
and acetone response to triglycerides, *134
adult-onset
and albumin antagonist, 386
and angiopathy, 825-837
and anhidrosis, *277
and anticoagulant therapy, *136
asymptomatic
and abnormal beta-glucuronidase activity, *527-528
and beta cell defect, *533-534
and beta cells, *674-675
and bladder, 331-334
and blood groups and genetic serum types, *355
and cancer, *521
and capillary changes, 595-597
and carbohydrate metabolism and lipid storage, *278-279
"chemical," *526
and glucose tolerance tests, *532
in Chinese hamsters, *673, *744, *816, *817
clearance and tubular reabsorption of phosphates in, *201
and Clinitest method, 557-559
and congenital malformation, 127-129
control, *892
and acetone in alveolar air, *747
and norethynodrel with mestranol, *675
and corticosteroids
and intraocular pressures, *355
and cortisol binding capacity, *888
detection
and blood sugar measurements, 219-226
and glucose-fucose response test, *506
and diabetes insipidus
and diguanides, *66
and diabetic amyotrophy, 181-189
diagnosis, *601, *529
of early asymptomatic, *65
and effects of age on glucose metabolism, 161-162
and laboratory procedures, *435
and T wave abnormalities, 722
and tolbutamide response, 15-17
and dietary hypercholesterolemia, *538
and dilantin, *533
and diuretic therapy, *435
early latent, *137
and employment, *603
etiology
and protein and fats, 232, 235-236
experimental
in hybrid mouse, *745
and eye, *741
and family history, 40-49, *525-526
and triamcinolone tests, 57-60
and weight changes, 594
and fat absorption, 455-460
and free fatty acids, *440
genetic
classification of, 540
and glomerular ultrastructure, 628-634
and glucagon, *206
and glucose tolerance
and estrogen, *525
and glucose tolerance tests, 175-180
and skinfold thickness, *435-436
and glucose transport, *602
and glycemia of infancy, *205
and glycerol metabolism, *358
and glycodiazine, *204
and gout and hyperlipidemia, *65
growth-onset, *531-532
and hepatic glutamic dehydrogenase, *278
and heredity, *278, 346-350, *742-743
and synalbumin insulin antagonist studies, *279
and hyper- and hypoglycemia, and beta cell degranulation, 493-497
and hyperinsulinemia
and growth hormone, *276
and hyperlipidemia and hyperglycemia, *505-506
and hypertension, *891
and potassium loading, *360
and hypopituitarism, *746
and I-131-insulin disappearance studies, *526-527
and insulin
abnormal, 572-575
antagonism, 483-485
antibody, 407
and glomerular filtration rate, 264-267
immunoreactive, 652-655
pancreatic, 687-693
requirements, 369
response to glucose, *813
response to hyperglycemia, 560-565
and islet and beta cell volumes, *672
and islet cell stimulation, *514
juvenile
and catecholamines, *504-505
and elevated GFR, 266
and insulin-like activity, 695-702
and offspring, *524
and optic atrophy, *205
and plasma studies, *890
and proliferative retinopathy, 728-732
and remission, *887
and skin capillary study, *675
survey, 111-114
and tolbutamide, 215-218
and vascular disorders, *889
kidney in, *205
latent
micturitional dysfunction in, *534-535
and lipemia, *672
lipoatrophic
and lipodystrophy, 715-720
and mental illness, 708
and lipodystrophy, 718
and lipoprotein lipase activity
and dextran sulfate, 239-241
long-term control
and blood sugar levels and glycosuria, 502-503
management, *820
and amputation, *136-137
and education of diabetic, 111-117
and employability, *66

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70	May, 283-368	September, 615-680
February, 71-140	June, 369-442	October, 681-752
March, 141-210	July, 443-544	November, 753-824
April, 211-282	August, 545-614	December, 825-896

and medication errors, 882-885
physiatrist's role, *66, *67
mass screening
and Dextrostix, *360
maternal
clinical study of infants, 306-311
maturity-onset
and chlorpropamide, 487-491
and insulin response to glucose, 466
and long-term acetohexamide, *206
and microangiopathy study, *748
and mitochondria, *742
and mortality, *525, *603, 875-881
and mumps, *438
and mutation, *672
neonatal
in half-sisters, *672
and nutrition, 738
and obesity, *206, *520, 600
and sulfonylurea and phenformin, *601
and thyroid autoimmunity, *531
and oral contraceptives, *440
and pancreas carcinoma, *135
pathogenesis, 615-626
and periodontal changes and dental caries, 804-809
and periodontal disease, 336-339
and phenelthylbiguanide, 302
and phenformin, *206, *820
and pheochromocytoma, *207
and pituitary ablation, 636-642, *815
and placenta, 227
and plasma growth hormone study, *66
and plasma insulin response to oral glucose, 466
potential
and pregnancy, *202, *278
and pregnancy, *356
prematurity-onset
and hyperglycemia, 268-271
and prepartum pituitary necrosis, *506-507
prevalence, *530-531
and serum uric acid, 858-867
in United States, *746
and protein-calorie deficiency, 105-106
and protein and carbohydrate loads, *522-523
and psychotherapy, *536
and renal papillary necrosis, 664-665
and sand rat, *814-815
screening
in elderly persons, *435
and serum cholesterol
and cardiovascular lesions, 71-81
and serum immunoreactive insulin response
and glucose infusions, 145-148
and serum insulin, *743
and serum lipids
and probenecid, *748
and sex incidence, 110
and siblings of diabetic children, 156-160
and skeletal changes, *438-439
and skin color, *437
and skin disorders, *358
spontaneous, *513-514, *745
in dogs and cats, *814
steroid-induced
and insulin, 18-20
streptozotocin-induced, 51-60, *512-513
and stress, *537
and sugar intake, 62-63
and sulfonylureas
and thyroid function, *887
surveys
in industrial population, 171-174
in South Africa, 191-196
and synalbumin insulin, 389-390
syndrome
in children, *744
in sand rats, *745, *815-816
and tolbutamide, *201
treatment
and glyhexamide, tolbutamide and chlorpropamide, *744
with tolbutamide and dicoumarol, 211-214
uncontrolled
eight-hour therapeutic regimen, 341-345
unstable
and blood glucose levels, *535
and growth hormone levels, *504
and Valsalva maneuver, 462-465
and vascular disease, *279
and foot lesions, *815
and weight reduction, *534
in Wellesley hybrid mouse, *814
and wounds
and local insulin application, *67

DIARRHEA
and cow's milk, *602
and disaccharidase deficiency, 482, 486
and steatorrhea, 459

DIAZOXIDE
and glucose U-C-14 utilization, 777-783
and insulin release, *277
metabolism, *748

DICOUMAROL
and tolbutamide effect, 211-214

DIET
of alloxanized rats
in stress study, 319
of animals in hypokalemia study, 312
atherogenic
and cardiovascular lesions in diabetic and nondiabetic rats, 71-81
canned food, 461
carbohydrate
and glucose tolerance, *888
corn oil
and fecal sitosterol and cholesterol, 627
and diabetes, 62-63, 738, *814
and diabetic amyotrophy patient, 182
and diabetic syndrome, *815-816
disaccharide
and carbohydrate absorption, *742
and glucose tolerance, 11, *355
and hereditary diabetes, 41, 49
high calorie
and fatty acid synthesis and gluconeogenesis, *137
high-carbohydrate, low-fat
and cholesterol, *134-135
and glucose tolerance, *134
high and low carbohydrate
and glucose insulin and triglyceride responses, *436-437
and hypoglucagonemia, *65
in insulin and nitrogen excretion study, 18
in ischemic heart disease, *204
of Lapp children, 318
low-protein
and glucose tolerance, 96-106
low sucrose, *279
and malnutrition therapy, 149
medium-chain triglycerides
and ketosis, *134
milk-free, 376
milk in, *602
and "moldy" peanut meal, 646
and plasma amino acid, *358, *819
of South Africans, 191
in uncontrolled diabetes regimen, 342
unsaturated fats, *134
and vascular disease, 836
yams
and liver necrosis, 575

DIETHYLPROPION
and obesity, *206

DIGUANIDES
antidiuretic effect, *66

DILANTIN
and diabetes, *533

DIOTHIOTHREITOL, 686

DIPHENYLTHIOCARBAZONE, 83-84

DISACCHARIDASE
in milk-sensitive and celiac patients, *602

DISACCHARIDES
deficiency
and diarrhea, 482, 486
localization of, *672
-tolerance tests, *742

DRUGS
insulin-dependent transport of, *515

DWARFISM
and diabetes, *744
and growth hormone
and nitrogen retention, *887
and hypoglycemia, *438
with normal pituitary function, 478-481

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70	May, 283-368	September, 615-680
February, 71-140	June, 369-442	October, 681-752
March, 141-210	July, 443-544	November, 753-824
April, 211-282	August, 545-614	December, 825-896

E

ELECTRIC SHOCK
and blood sugar response
in normal, adrenalectomized and hypophysectomized white rats, 325-330
and glycosuria and blood sugar, 319-328

ELECTROCARDIOGRAPHY
and glucose ingestion, *889
T waves
and diabetes diagnosis, 722-727
and Valsalva maneuver and diabetes study, 465

ELECTROPHORESIS
paper
and aminoacidurias screening, 417

ENDOCRINE GLANDS
adenomata, *505

ENOVID, *137

ENZYMES
and ATP formation by glycolysis, 21-24
gastrointestinal
and insulin release, 377
and gluconeogenesis, 255-256
and glucose feeding, *819
and glycogen storage disease, *67
glycogen-synthesizing, 369
hepatic gluconeogenic
and tumors, *207
inactivation
and alloxan, 88
inhibition
and diguanides, *66
and insulin-like activity, *357
liver phosphorylase assay, *133
proteolysis
and insulin measurement, 656-663
release
and lipolytic hormones, *67
in tumor cells, 411-413

EOSINOPENIA
and glucose tolerance tests, *886

EPINEPHRINE
and blood pressure, *505
and diabetogenic effect of alloxan, 130-131
and fat cell metabolism, *743
and glucose uptake, 32
and hypoglycemia, *435
and insulin release, *436, *603, *675
lipolytic effects, 584-586
and 3-0-methylglucose penetration into muscle, *514
and permeability of muscle to sugar, 29
release
and diazoxide, *277
and lipolytic hormones, *67

ESTROGEN
and glucose tolerance, *440, *525
and serum lipid levels, *204

ETHANOL
and hepatic gluconeogenesis, *528
and hypoglycemia, 252-257, *439
and phenformin
and obesity, *508
and plasma lipids, 39

N-ETHYLMALEIMIDE
and inhibition of insulin I-131 degradation, 29

EXERCISE
and glucose tolerance, *521-522
and glycogenosis, *891

EYE
atrophy
and juvenile diabetes, *205
diabetic changes, *741
and glaucoma and phenylthiourea taste sensitivity, 20, 25, 324

F

FAMILY HISTORY
and congenital malformations, 127
and diabetes, 40-49, *278
and glaucoma, 20, 25
and glucose tolerance tests
in children, 11-14
in industrial population, 171-174
in siblings of diabetic children, 156-160
in hyperglycemia study, 233
and hyperlipidemia and hyperglycemia, *506
and insulin hypersecretion, *522
and latent diabetes, *137
and lipoatrophic diabetes and mental illness, 708-713
and neonatal diabetes, *672
and serum insulin, *524
and siblings of diabetics, *526
and synalbumin insulin antagonist study, *279
and triamcinolone provocative tests, 57-60
and weight changes
and oral contraceptives, 594

FATTY ACIDS
absorption
and diabetes, 455-460
of adipose tissue, *674
biosynthesis
and obesity, *816-817
free, *672
and arginine, 480-481
and carbohydrate metabolism, 765-774
in diabetic Chinese hamsters, *673
and diabetic obesity, *601
and diabetic rats on atherogenic diet, 72
during glucose tolerance tests, 175-180
and glucose, 576-588, *820, *888
and hyperglycemia, 232-236
and infants of diabetic mothers, 308, 310
and isoproterenol infusion study, 150-154
and methylprednisolone, *520
and protein, 753-763
and protein and carbohydrate loads, 522-523
and protein release, *67
turnover rate, *440
and gluconeogenesis, *507
glucose-U-C-14 conversion to, 777-783
and insulin-like activity, *814
metabolism
in alloxan diabetes, 90-95
and denervation, 259-263
mobilization
and hydrogen production, *440
and re-esterification and glucocorticoid hormones, *744
nonesterified
and glucose ingestion, *744
and glucose uptake on muscle, 427
and growth hormones, *276
and low-protein diet study, 98, 100
and tolbutamide, 216-218
oxidation
and glucose metabolism, *279
release
and ethanol, 39
response to glucose, 562
synalbumin-nonesterified
and insulin-like activity, 426-427
synthesis and gluconeogenesis
and high-calorie diet, *137

FETUS
of diabetic rats, 227-231
glucose and fructose metabolism, *133
insulin
and glucose, *516-517
loss
and diabetic pregnancy, 61
and maternal glucose-loading, *359-360
pancreas cultures
and glucose, 846-850
rat
and glucose infusion, 839-845

FIBRINOLYSIS
and portal cirrhosis, 776

FRIEDREICH'S ATAXIA, *205

FRUCTOSE
and glycogenesis, 791
and intestinal resorption
and insulin, *357
metabolism
in sheep fetuses, *133
and serum lipid levels, *204

FUROSEMIDE
and glucose metabolism, *820

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70	May, 283-368	September, 615-680
February, 71-140	June, 369-442	October, 681-752
March, 141-210	July, 443-544	November, 753-824
April, 211-282	August, 545-614	December, 825-896

G

GALACTICOL
and galactosemia, *278

GALACTOSE
and glycogenesis, 791
toxicity
and myoinositol metabolism, *820

GALACTOSEMIA
and galacticol, *278
screening test, *437

GANGRENE, *358

GASTROINTESTINAL TRACT
and disaccharidase, *672-673
and glucagon distribution, *137
hormones
and plasma insulin, *527
and insulin passage, *813-814
resorption of glucose and fructose and insulin, *357
and steatorrhea, 460

GENES
and diabetes, 40-49, 346-350, 615, *672
and juvenile diabetes mellitus with optic atrophy, *205
and siblings of diabetic children, 156

GLAUCOMA
and phenylthiourea taste sensitivity, 20, 25, 324

GLOMERULI
of diabetic Chinese hamsters, *816
and insulin, *887

GLOMERULAR FILTRATION RATE
and diabetes, 264-267

GLOMERULOSCLEROSIS, 828
diabetic
and insulin, 264
and pituitary ablation, 636-642

GLUCAGON
and antiglucagon, *65
beta-cytotropic effects, *892
and gluconeogenesis, *522
and glucose uptake, 31
and hepatic glutamic dehydrogenase, *278
and hypocalcemia, *439
and hypoglycemia, *601
immunoassay, *205
in gastrointestinal tissues, *137
and insulin release, 153, *206, 283-288, *436, 449-453
-like immunoreactivity, *517
mode of action, *528
and muscle permeability to sugar, 28
and obesity, 666-669
in pancreas, gut, and plasma, *747-748
and pregnancy, *891
release
and islets of Langerhans, *518
and lipolytic hormones, *67
pancreas carcinoma, *135
and sympatho-adrenal system, *357

GLUCOCORTICOIDS
and fatty acids, *744
and gluconeogenesis, *817
and plasma insulin, *204

GLUCONEOGENESIS
and ethanol, 252-257, *528
and glucagon and corticosteroids, *522
and glucocorticoids, *817
and high caloric diet, *137
and hydrazine, *276
stimulation of, *507

β-GLUCURONIDASE, *527-528
and alloxan diabetes, *134

GLUCOSE
and alcohol, 252-257
arterial, and hydrazine, *276
and beta cell granulation, 839-845, 846-850
beta-cytotropic effects, *892
consumption
by polymorphonuclear leukocytes, *887
disappearance
and pancreatectomy, 552
exogenous
and glucose metabolism, *275
and fatty acid response, 562-563
-fatty-acid cycle hypothesis, 765
and fatty acid synthesis, *816
flow of carbon atoms from, *888
-fucose response test, *506
and glucagon, 284-285
homeostasis in newborn puppy, *201
infusion
and isoproterenol, 150-154
and serum insulin response, 145-148
ingestion
and electrocardiograms, *889
and insulin response
computer model for, *813
and intestinal resorption
and insulin, *357
and insulin-like activities, *277
and insulin release, 377-384
and insulin response, 560-562, *887
and insulin secretion, *510-511
and pancreozymin, 141-144
-insulin tolerance tests and low-protein diet, 98
intolerance
and insulin, *742
and stress, *672
and lipolysis, *888
loading
and corticoids, *520
and enzymes, *819
and islet damage, 21
maternal, *359-360
oral and intravenous differences, 141
and plasma growth hormone, *66
metabolism
and acetate, *202
and carbon dioxide, *890
and furosemide, *820
and glucose loading, *820
in sheep fetuses, *133
oxidation
and prostaglandins, *202-203
phosphorylation
and insulin secretion, *505
plasma insulin response to, 466-471
production
determinations, *507-508
and serum lipid levels, *204
and tolbutamide
and insulin release, *509-510
tolerance
and abdominal surgery, *136
and acetohexamide, *206
and age, 161
and albumin, 390-391
and atherosclerosis, *277-278
and carbohydrate, *888
and diet, *355
and dietary carbohydrate study, *134
and diuretics, *435
and estrogen, *525
and exercise, *521-522
and heredity, 615
and hormones, *742
and hypercholesterolemia and gout, *65
and insulin-activity, *512
and low-protein diets, 96-106
and malignant blood dyscrasias, *135
in Negro men deficient in glucose-6-phosphate dehydrogenase, *203
in normal and partially pancreatectomized rats, *387
and oral contraceptives, *439-440, *603
and pancreatectomy, *511-512
and potassium deficiency, *510
and tolbutamide in ischemic cardiovascular disease, 15-17
and triglycerides, 796-803
tolerance tests
afternoon, *532
and blood sampling technics, 219-226
and carbohydrate, *436-437
compared with triamcinolone tests, 59
and cortisol, 566-567
and diabetes diagnosis, *601, 620
and diabetes survey, 860
of diabetic pregnant women, 306
and electrocardiograms, 723-726
and familial aggregation study, 41
and free fatty acid changes, 175-180
and glucose load disposal, *435-436
in industrial population, 171-174
and insulin-like activity study, 695-696
intravenous, *276

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70
February, 71-140
March, 141-210
April, 211-282
May, 283-368
June, 369-442
July, 443-544
August, 545-614
September, 615-680
October, 681-752
November, 753-824
December, 825-896

of mothers of congenitally malformed infants, 127-129
and normal children, 11-14
and ocular hypertension, *886
in offspring of diabetic parents, *524
and oral contraceptives, *136, *440
and pancreatectomy, 551-556
and phenethylbiguanide, 302
and postgastrectomy patients, *67
and pregnancy, *360
and relatives of diabetics, *137
in siblings of diabetic children, 156-160
and squirrel monkeys, 397-398
and sugar intake, 62-63
and synalbumin insulin antagonism, *674
during tularemia, 370
transport, *602
and insulin-like activity, 427-428
turnover, *889
and Cori cycle, *889
uptake
and albumin, *275
and caffeine, *355
forearm, *361
in frog sartorius muscles, 26
in perfused rat heart, 547
and phenethylbiguanide, 303-304
of rat hemidiaphragms, 30-32
and tryptophan metabolites, *892
utilization
and cortisol, *134
and ethanol, *439
and free fatty acids, 765-774
and insulin, 418

GLUCOSE-C-14
disappearance, 546-547
turnover, *889

GLUCOSE-I-C-14
oxidation
and prostaglandins, *202-203
uptake
and caffeine, *355

GLUCOSE-6-PHOSPHATE
dehydrogenase activity, *275, *603
and glucose tolerance, *203
and insulin and alloxan diabetes, *65

GLUCOSE-6-PHOSPHATASE
and glycogen storage disease, *67

GLUCOSE-U-C-14
metabolism by adipose tissue, *65-66
utilization
and diazoxide, 777-783

6-GLUCOSIDASE
and glycogen storage disease, *67

GLUCOSURIA
and atherogenic diet, 73

GLUTAMATE
and sugar transport, *135

GLUTATHIONE
and I-131 insulin degradation, 29
and plasma insulin activity, 418

GLYCEMIA
and periodontal disease, 339

GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE, 22-23

GLYCEROL
levels
and isoproterenol infusion, 151
metabolism
and diabetes mellitus, *358

GLYCODIAZINE, *204

GLYCOGEN
in diabetic rat placenta, 229
flow of carbon atoms, *888
and hydrazine, *276
infiltration of beta cells
and hyper- and hypoglycemia, 493-497
nephrosis, 51
storage disease, *276
and enzymes, *67
stores
and infection, 369
synthesis
and insulin, 418

GLYCOGENESIS, *891
and malnutrition, 96
and serum insulin, 791-794

GLYCOGENOLYSIS
and adenosine-3',5'-monophosphate, *275

GLYCOLYSIS
ATDP formation by, 21-24
and insulin deprivation, 475

GLYCOSURIA
and alloxan diabetes, 84
and blood sugar, 502-503
and electric shock stress, 319-323
and cortisone, *276
and insulin, 18-20
and diabetic amyotrophy case, 181
and heredity, 615
and infection, 369
and insulin response study, 146
and siblings of diabetic children, 159-160
and stress, 323
and sugar intake, 62

GLYHEXAMIDE
and diabetes, *744

GOUT
and hyperlipidemia and diabetes, *65

GROWTH
and diet, 318
and growth hormone deficiency, 478
and hypokalemia, 314

GROWTH HORMONE
activity
and acetyl proteins, *207
assay
"tibia test," *133
and diabetes, *276
and fasting and glucose loading, *66
and fat mobilizing, *504
and hexose metabolism, *356
and hypoglycemia, *435
and glucose uptake, 30
in hypopituitary children, *202
in hypopituitary diabetics, *206, *746
immunoassay, *437, 734-737, *886-887
and infants of diabetic mothers, 307-309
and insulin deficiency, 478-481
and insulin release, *603, *673
and lipid metabolism and urea formation, *358
and lipoatrophic diabetes, *533
and malnutrition, 149, 155
metabolic effects, *207
and nitrogen retention, *887
and prediabetes, 615
and protein-calorie deficiency, 104
release, *439
and starvation, *359
in thyrotoxicosis, *275

H

HAMSTERS, CHINESE. *See* Chinese hamsters

HEART
in insulin distribution study, 405-407
perfused
and anti-insulin serum study, 475-477
and insulin and insulin-like activity, 545-549
perfusion technic, 476
rat
carbon flow, *888
rate
and Valsalva maneuver, 462

HEART DISEASE
coronary
and carbohydrate and lipid metabolism, *505
and glucose tolerance survey, 171-174
and metabolism, *537
and diabetes, *603
ischemic
and plasma triglyceride, *204

HEPARIN
and free fatty acids and ketones, *275

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70	May, 283-368	September, 615-680
February, 71-140	June, 369-442	October, 681-752
March, 141-210	July, 443-544	November, 753-824
April, 211-282	August, 545-614	December, 825-896

HEPATOMEGALY, *278
and lipodystrophy, 718

HEREDITY
and diabetes, 40-49, 156, 346-350, *524, 615-626, *742-743, 829
and blood groups and genetic serum types, *355
neonatal, *672
and triamcinolone tests, 57-60
and fatty acid metabolism, *675
and glaucoma, 20, 25, 324
and hypertension
and glucose tolerance, *886
and insulin response, *813
and lipoatrophic diabetes and mental illness, 708-713

HEXOKINASE
isolation and purification of, *816

HEXOSE
metabolism
and insulin and growth hormone, *356
monophosphate shunt, *275
and pancreatic islets, 21

L-HISTIDINE
and sugar transport, *135

HISTIDINEMIA
and amino acid disorders, *356

HOMOCYSTINURIA
and amino acid disorders, *356

HORMONES
anabolic
and liver glycogen, *537-538
assays
and "tibia test," *133
balance
and liver vitamin A, 704
beta adrenergic
and insulin release, 150-154
Enovid
and plasma insulin and blood glucose, *137
estrogen-progestin
and glucose tolerance, *136
glucocorticoid
and fatty acids, *744
and gluconeogenesis, *522
and glucose tolerance, *742
and hyperglycemia, *515
intestinal
and insulin secretion, 141-144
and plasma insulin, *527
and lipoatrophic diabetes, 720
lipolytic
and protein release, *67
ovine growth, *201-202
pituitary
and blood glucose and plasma insulin, *359
protein
immunoassay, 734
and sex difference in diabetes incidence, 110
thyroid
and alloxan, *356

HYALINE MEMBRANE DISEASE, 308

HYDRAZINE
and liver glycogen, arterial glucose, lactate, pyruvate and acid-base balance, *276, *743-744

HYDROCORTISONE
and cartilage growth, *133

β-HYDROXYBUTYRATE
and protein synthesis, 758

HYDROXYHEXAMIDE-C-14
in acetohexamide study, 118-126

HYDROXYKYNURENINURIA
and amino acid disorders, *356

HYDROXYPROLINEMIA
and amino acid disorders, *356

HYPERCHOLESTEROLEMIA
and atherosclerosis, *521
in diabetic rats, *538
and glucose tolerance, *65
and pancreas blood diversion, *675
and probenecid, *748
and retinopathy, 729-730

HYPERGLUCAGONEMIA
and pancreas carcinoma, *135
and pancreatitis, *439

HYPERGLYCEMIA
and acute myocardial infarction, *743
and alloxan diabetes, 84
and amino acid disorders, *356
and arginine, 268-271
and atherogenic diet, 73
and ATP formation in islets, 21-24
and beta cell degranulation and glycogen infiltration, 493-499
carbohydrate-induced
and fat and protein, 232-236
in chronic-denervated-liver animals, 262
and cortisol, 566
and diabetes, *505-506
in middle-aged diabetics, 21
in pregnant diabetics, 309
and dilantin, *533
epinephrine-induced, *513
and heredity, 615
and hyperinsulinemia, *438
and insulin response, 560-565
to glucagon, 285-286
during glucose infusions, 145-148
and islets of Langerhans, *746
and obesity, *673
and ovine growth hormones, *201-202
and pancreas and serum insulin activity, *818-819
and pancreatic glucagon, *517
in pregnant diabetics, 309
and prostaglandin, *515
and pyruvic acid phenylhydrazone, *355
and siblings of diabetic children, 157
streptozotocin-induced, 51-60
and stress, 323
temporary idiopathic neonatal, *277

HYPERINSULINEMIA
and amino acid, *356
and diabetes, *276
and hyperglycemia, *438
and infants of diabetic mothers, *819

HYPERKETONEMIA
and triglycerides, 796-803

HYPERLACTICACIDEMIA
and uric acid excretion, *276

HYPERLIPEMIA
and lipodystrophy, 718

HYPERLIPIDEMIA
and coronary heart disease, *537
and diabetes, *505-506
and gout and diabetes, *65
and pancreas blood diversion, *675

HYPERPITUITARISM
and diabetes diagnosis, *601

HYPERPROLINEMIA
and amino acid disorders, *356

HYPERTENSION
and diabetes, *891
and eight-hour regimen, 344, 345
and potassium-loading, *360
and diabetic pregnancy, 61
and diuretic therapy
and glucose tolerance, *435
ocular
and glucose tolerance tests, *886

HYPERTRIGLYCERIDEMIA
carbohydrate-induced
in ischemic heart disease, *204
and glucose tolerance, *65
and probenecid, *748

HYPERURICEMIA
in glycogen-storage disease type I, *276
and probenecid, *748

HYPOCALCEMIA
glucagon-induced, *439

HYPOGLUCAGONEMIA
and diet, *65

HYPOGLYCEMIA
and acetohexamide, *66
and adipose tissue extracts, *886
alcohol and, *205-206
and beta cell degranulation and glycogen infiltration, 493-499
and carbohydrate and lipid metabolism, 312-317

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70
February, 71-140
March, 141-210
April, 211-282
May, 283-368
June, 369-442
July, 443-544
August, 545-614
September, 615-680
October, 681-752
November, 753-824
December, 825-896

in children, *436
and cortisol production rate, *438
and disodium EDTA, *891
and ethanol, *508
ethanol-induced, *439
and hepatic gluconeogenesis, 252
glucagon, *601
and glycogenosis, *891
and growth hormone, *439, *504, *533, *675
idiopathic
and diabetes, *205
and infants of diabetic mothers, 308
insulin-induced
in dogs on low-protein, 100
and growth hormone, *275
and insulin and sulfonylureas
and monoamine-oxidase drug, 272-274
neonatal
and glucose homeostasis, *201
incidence, *440
and pancreatectomy, *438
and phenethylbiguanide, 302
prognostic and etiologic factors, *674
and propranolol, *435, *438
and ribose, *748
and stress, *672
tolazamide-induced, 352
and tolbutamide and dicoumarol, 211-214
and tolbutamide tolerance tests, *816
and tumors, 416
and vagal stimulation, *447
and zinc glucagon, *135, *136

HYPONATREMIA
and pituitary stalk section, *524

HYPOPHYSECTOMY
and diabetic retinopathy, *538-539
anl electric shock stress, 325-330
and growth hormone study, *203
and proliferative retinopathy, 731-732

HYPOPITUITARISM
and diabetes, *746
etiology, *438
and glucose-6-phosphate dehydrogenase, 603
and growth hormone
and placental lactogen study, *206
and prolactin, *202

HYPOTENSION
and diabetes, *66
and dilantin, *533

HYPOTHALAMUS
and blood glucose regulation, *443
lesions
and insulin sensitivity, *741

HYPOTHERMIA
and stress, *672

HYPOTHYROIDISM
and glucose-6-phosphate dehydrogenase, *603

HYPOTONIA
and diabetes, *744

I

IMMUNITY
against insulin, 402-407

INFANTS
with congenital malformations
and maternal carbohydrate metabolism, 127-129
and copper deficiency, 851, 874
and diabetes
and mumps, *438
of diabetic mothers, 306-311, *360
and plasma insulin and glucose, *439-440
and fatty acid metabolism defect, *675
and galactosemia, *278
and growth hormone and malnutrition study, 149, 155
and hyperglycemia, *277
and hypoglycemia, *440
and diabetes, *205
malnutrition
and thyroid gland, 335
nutrition and linoleic acid, 492, 501
of prediabetic mothers, *133-134
premature, *440

INFECTION
and protein deficiency, 100, 104-105

INSULIN, *359
abnormal
and diabetes, 572-575
action
and salts of EDTA, *891
in mitochondrial systems, *203
and obesity, *818-819
and adipose tissue metabolites, *65, *890
and adrenal stimulation, *357
alpha and beta chain
activity, *204
antigenicity, *820
and amino acids, *359
antagonism
and congenital deformities, *360-361
and diabetes, 483-485
and synalbumin, 386-393
antagonists
artifactual, 289-300
antibodies
and source of insulin, *276
and anti-insulin serum, *207
assays, *602
and enzyme proteolysis, 656-663
of islet-cell tumors, 412
and tolbutamide, 217, 218
in vitro, 418-422
and beta cell study, 494
binding
estimating methods, *530
biosynthesis
and isolated islets of Langerhans, 38
by perfused dog pancreas, 647-650
and bladder function study, 333
bovine
equilibrium ultracentrifuge study, *203
and brain metabolism, *437
carboxypeptidase A study, *206-207
clearance and metabolic action, 545-549
content
of tumors, 415-417
in cord plasma, 308, 309-310
crystalline
assay, *67
deficiency
and growth-onset diabetes, *531-532
and testosterone action, *741
degradation
and alloxan, *513
-dependent drug transport, *515
and diabetes management, 112
disappearance curve
and renal disease, *439
dosage
history of unit, 198-200
and uncontrolled diabetes regimen, 341
errors, 883-884
exogenous
effect on rat placenta, 227-231
extracellular
and pancreatectomy, *511-512, 551-556
fetal-maternal
and glucose, *516-517
and glomerular filtration rates, 264-267
and glucose and ketone production, *507
and glucose metabolism, *137
-glucose tolerance tests
and phenethylbiguanide, 302
and glucose uptake
and nephrectomy, *741-742
and growth hormone
immunoassay, *437
and hexose metabolism, *356
hypersecretion, *522
hypoglycemia
and monoamine-oxidase inhibitor drugs, 272-274
immunity
and organ distribution of insulin, 402
immunoassays, 734-737
double antibody technic, *201
immunoreactive
and chlorpropamide, 487-491
disappearance in normal and adult-onset diabetics, 652
and D-ribose, *748
and isoproterenol infusions, 151-154

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70	May, 283-368	September, 615-680
February, 71-140	June, 369-442	October, 681-752
March, 141-210	July, 443-544	November, 753-824
April, 211-282	August, 545-614	December, 825-896

in prediabetes, *535
and prolonged glucose infusion, 145-148
in twin siblings of diabetics, *526
-induced hypoglycemia
and growth hormone, *275
inhibition
and pituitary and adrenal influence, *523
insufficiency
and liver glucokinase, *439
and intestinal resorption of glucose and fructose, *357
and kidneys, *887
-like activity, 418
and adipose tissue, *358
and albumin, *275
assay, *67
in blood, *66
in children, 695-702
and 2-deoxyglucose, 379-384
and enzymes, *357
and glucose and D-mannoheptulose, *277
and insulin antagonist study, 289-300
and insulin and glucose tolerance, *512
and isolated fat cell method, *814
sites, *745
and starvation, *536
and liver vitamin A, 704-707
and lipemia, 90
and muscle permeability to sugar, 26-32
and nephropathy, 265-266
and nitrogen excretion, 18-20
from nondiabetic and diabetic pancreas, 687-693
and obesity, *891
ox
iodination of, *601
and pancreatectomy requirement, *360
and phenylethanolamine-N-methyl transferase, *529
and placenta, 227-231
in plasma of newborn infants, *439-440
and plasma triglycerides, *889-890
-producing tumors, *136
production
by adult-rat islets of Langerhans, *203-204
and protein release, *67
and protein synthesis
and amino acid metabolism, 753-763
radioimmunoassay
of A-chain, 681-686
in urine, *891-892
requirements
and stress, *537
release
and ACTH, glucagon and adenosine-3'-5'-phosphate, 449-453
and beta adrenergic stimulation, 150-154
and 2-deoxyglucose, *277
and epinephrine, *675
and glucagon, *206, *436
and growth hormone, *603
and islets of Langerhans, 37, *518
and metabolizable sugars, tolbutamide, and 2-deoxyglucose, 377
and octanoate, *892
and thiazides, *435
resistance
psychotherapeutic intervention, *536
response
in adipose tissue study, *65-66
and diet, *436-437
to glucagon, 666-669
to glucose, *813, *887
to hyperglycemia, 560-565
and potassium deficiency, *510
and prediabetes, 615-619
to protein, 232-236
and stress, *672
and tularemia, 369-375
secretion, *505, *516
ACTH-mediated, *815
and amino acids, *356, *510
and calcium and magnesium, *357-358
and Chinese hamster pancreas, *745-746
and diazoxide, *277
and epinephrine, *436
and glucagon, 283-288
and glucose and tolbutamide, *509-510
and growth hormone deficiency, 478-481
measurement, *602
and pancreozymin, 141-144
regulation, *511, *744
and secretin, *435
and thyroid function, 643-645
and tolbutamide, *511
and vagus nerves, 443-448, 852
sensitivity
and hypothalmic lesions, *741
sources
and fetus and placenta, *359
and sulfonylureas, *201
"suppressible-nonsuppressible," 423-426
and synalbumin antagonism
and prediabetes, *279
synthesis
and peptides, *277
solid phase method, *278
tolerance
and adrenalectomy, *746-747
tolerance tests
and low-protein diet study, 98, 100
and phenethylbiguanide, 302
in triglyceride metabolism study of alloxan diabetes, 90-95
and uremia, *742
urine, *747
and weight reduction, *534
and wounds, *67

INSULIN-I-125
in insulin distribution study, 403-407
and radioimmunoassay of insulin A-chain, 681-686

INSULIN-I-131
absorption, *888-889
binding, *361
degradation by muscle extracts, 27, 29-30
disappearance studies, *526-527
intestinal pathway, *813-814
labeling of ox insulin, *601
-triolein test, 455, 458

IODINE MONOCHLORIDE, *601

ISLETS OF LANGERHANS
and alloxan diabetes in mice, 83-88
alpha-cell carcinoma, *135
and diabetes, *814
and hyperglycemia, *746
and insulin and glucagon release, *518
method of isolation from rat pancreas, 35-38
and spontaneous lesions in rats, 108-110

ISOPROTERENOL
and insulin release, 150-154

ISRAEL
ischemic heart disease
and hypertension study, 858-867

J

JAUNDICE, *278
and infants of diabetic mothers, 308

K

KETOACIDOSIS
diabetic, *438

KETOGENESIS
and liver denervation, 259-263

KETONEMIA
and pancreatectomy, 262-263

KETONES
in idiopathic hyperglycinemia case, *135-136
and insulin release, 377

KETONURIA
and atherogenic diet, 73

KETOSIS
and insulin response, 468
and medium chain triglycerides, *134
and plasma study, *890

KIDNEY
and antiglucagon study, *65
arteriolar and glomerular lesions
and pituitary ablation, 636-642
and blood glucose homeostasis, *507
and diabetes, *205
disease

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70	May, 283-368	September, 615-680
February, 71-140	June, 369-442	October, 681-752
March, 141-210	July, 443-544	November, 753-824
April, 211-282	August, 545-614	December, 825-896

and insulin I-131 disappearance, *439
and pregnancy, *67
glomerular, 628-634
B-glucuronidase
and alloxan diabetes, *134
and insulin, *887
in insulin distribution study, 405-407
papillary necrosis, 664-665
and streptozotocin-induced diabetes, 53-56

KIMMELSTIEL-WILSON SYNDROME, *525, 828

KWASHIORKOR
and glucose tolerance, 96

L

LACTATE
and fatty acid synthesis, *817
and hydrazine, *276
metabolism
and alcohol, 784-790

LACTOGEN
and metabolism, *886

LACTOSE
tolerance, *602

LAURENCE-BIEDL SYNDROME, *205

LESIONS
arterial
and retinopathy, 5
arteriolar and glomerular
and pituitary ablation, 636-642
and biochemical changes, *748
capillary
in diabetes, 194-196
cardiovascular
and diabetes and serum cholesterol, 71-81
in squirrel monkeys, 400
and diabetic amyotrophy, 189
in diabetic rats, 51-60
foot, *815
glomerular, 628-634
glomerular
and diabetes, *205
hypothalamic, *741
of islet of Langerhans in rats, 108-110
necrotic
and yams, 575
vascular
and diabetes, 264, 266

LEUCINE
and protein synthesis, 756-757
-sensitive hypoglycemia, *135

LIPEMIA
and diabetes, *672
and diabetic acidosis, *534
and glucose and insulin, 90

LIPIDS
and alcohol ingestion, 39
C-14-O_2 and C-14 content, 473
metabolism, *531
and antiglucagon, *65
and coronary artery disease, *505
and diazoxide, *748
and growth hormone, *358
mobilization
and partial lipodystrophy, *523-524
storage
and diabetes, *278-279

LIPOATROPHIC DIABETES
and growth hormone stimulation, *533

LIPODYSTROPHY, *358, *523-524, 715-720

LIPOGENESIS
and alcohol and acetate, *508
in obese mice, *817

LIPOID PROTEINOSIS, *358

LIPOLYSIS
and adipose cells, *889
in brown fat cells, *743
and glucose, *888
and prostaglandins, *202-203
in rat adipose tissue
and insulin, *359

LIPOPROTEIN
congenital absence of, 474, 477
lipase
and alloxan diabetes, 93-94
and dextran sulfate, 239-241
in human adipose tissue, *136
and reduction of serum triglycerides, *134

LIVER
and alcoholism, 39
and amino acid uptake, *359
and antiglucagon, *65
and atherogenic diets, 74-75
cirrhosis
and diabetes diagnosis, *601
and myocardial infarction, 776
corticoids and lipid metabolism, *531
denervation
and fatty metabolism, 259-263
glucokinase
and insulin insufficiency, *439
gluconeogenesis
and amino acids and insulin, *536
and ethanol-induced hypoglycemia, 252-257
and glucagon and corticosteroids, *522
glucose
and ethanol, *439
and free fatty acids, 765-774
and insulin, glucagon and anti-insulin serum, *507
and islet tumors, 417
β-glucuronidase
and alloxan diabetes, *134
glutamic dehydrogenase
and glucagon-loading, *278
glycogen, *201
and alloxan diabetes, *747
and deoxycorticosterone acetate, 312
in sheep fetuses, *133
and steroids, *537-538
in insulin distribution study, 405-407
and insulin secretion, *744
and iron absorption, 651
islet cell tumors
successful removal, 598
lipids
and growth hormones, *276
metabolism
and hydrazine, *748-744
necrosis
and yams, *575
and oxidation of tolbutamide, 211, 213-214
phosphorylase, *133
potassium
-deficient, *510
and hypokalemia, 315
rat
and alcohol, 784-790
vitamins
and insulin, 704-707

LUNGS
alveolar air acetone, *747
in insulin distribution study, 405-407

M

MAGNESIUM
and insulin secretion, *357-358

MALNUTRITION
and glucose tolerance, 96-106
and growth hormone therapy, 149, 155
in infants
and thyroid gland, 335

MANNOHEPTULOSE
and insulin-like activity, *277

D-MANNOSE
transport
and amino acids, *135

MENINGITIS
and cerebrospinal glucose uptake, *887

MENOPAUSE
and serum lipid levels, *204

MENTAL ILLNESS
and diabetes diagnosis, 723-727
and lipoatrophic diabetes, 708-713

MENTAL RETARDATION
and diabetes, *744

MESTRANOL, *525
and diabetes, *675

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70	May, 283-368	September, 615-680
February, 71-140	June, 369-442	October, 681-752
March, 141-210	July, 443-544	November, 753-824
April, 211-282	August, 545-614	December, 825-896

METABOLISM
acetate-1-C-14, *202
acetohexamide, 118-126
adipose tissue
and thyroid function, *889
amino acids
and free fatty acids, 753-763
and biguanides, *515-516
brown fat cells, *743
carbohydrate
and adipose tissue study, *65-66
and age, 161-169
and chronic uremia, *510
and coronary artery disease, *505
and diabetes, *278-279
and ethacrynic acid, *602-603
and glucose tolerance, 96-106
and hypokalemia, 312-317
impairment in squirrel, 395-401
and infection, 369
and male rats, 110
and malignant blood dyscrasias, *135
and metabolic fuels, 765-774
in mothers of congenitally malformed infants, 127-129
and nervous system, *443
and oral contraceptives, *440, 590-594
of pancreatic islets, 21-24
carbohydrate and lipid
and antiglucagon, *65
and hypokalemia, 312-317
and prostaglandins, *202-203
and carbutamide, *355-356
citrate, *743
and diabetes, 829-831
diazoxide, *748
fatty acid
inborn error, *675
galacticol
and galactosemia, *278
glucose
and anti-insulin serum, 472-473, 475-477
and exogenous glucose, *275
and insulin and dialysis, *886
and insulin stimulation, *137
glucose and fructose
and sheep fetal blood, *133
glucose-I-14-C
and caffeine, *355
glycerol
and diabetes, *358
and growth hormones, *207
hexose
and insulin and growth hormone, *356
of isolated fat cells, *67
ketone body, lactate and pyruvate
and alcohol, 784-790
lipid, *509, *531
and carbohydrate metabolism, *279
and ethanol, 39
and hypokalemia, 312-317
in obese forearm, 484
and obese hyperglycemia, *673
of perfused livers
and butylbiguanides, *817-818
phenformin, *741, 869-873
and placental lactogen, *886
and prediabetes, 615-616
and premature coronary disease, *537
and serum and urine citrate levels, *509
triglyceride
in alloxan diabetic rats, 90-95
of tumor-bearing animals, 415-417
zinc
and diabetes, *601-602

METABOLITES
assay in adipose tissue, *65

METHIONINE
and sugar transport, *135

3-O-METHYL-D-GLUCOSE 3-H
and sugar permeability study, 26-32

3-METHYLGLUCOSE
permeability of frog sartorius muscles, 27

METHYLPREDNISOLONE, *520

5-METHYLPYRAZOLE-3-CARBOXYLIC ACID, *524-525

MICROANGIOPATHY, 827-829
and arterial fluorescein studies, 2-3
diabetic
and nailfold capillaries, 595-597
and pituitary ablation, 642
in young diabetic men, *748

MICROSCOPY
and beta-cell islet tumors, 800-803
electron
of arteriolar and glomerular lesion, 637-642
of diabetic rat placenta, 228-230
and glomerular lesions, 628-634
of pancreas beta cells, 243-249
of skin capillaries, *675
of islet cell tumors, 410-412
light
of pancreas beta cells, 243
of skin in diabetes, *748
light and electron
of isolated islets of Langerhans, 36-37, 38
of lesions in diabetic rats, 51-60
of muscle tissue from diabetic amyotrophy patient, 182-189
and nailfold capillaries, 596
in ultrastructure study of dermal capillaries, 194-195

MINERALS
copper
and infants, 851, 874
iron
absorption, 651
from petroleum, 795
retention in malnutrition, 149

MITOCHONDRION
and insulin action, *203
respiration and phosphorylation, *742

MONOAMINE-OXIDASE
and hypoglycemia, 272-274

MORTALITY
in diabetes, *525, *603, 875
and diabetic pregnancy, 61
of diabetic rats on atherogenic diet, 72-73
fetal, *137
in diabetic pregnancy, 61
of infants of diabetic mothers, 306
and renal papillary necrosis, 664-665
in streptozotocin-induced diabetes, 54
and vascular disease, *67, 826

MOUTH
periodontal changes and dental caries and prediabetes, 804-809

MUMPS
and pancreatitis and diabetes, *438

MUSCLE
acid-base balance and electrolytes
and sodium bicarbonate and sodium lactate, *135
amyotrophy
in diabetic, 181-189
frog sartorius
and insulin-131-I, *361
glucose uptake
and fatty acids, 427
in insulin distribution study, 405-407
3-0-methylglucose penetration
and epinephrine, *514

MYOCARDIAL INFARCTION
and diabetes, *743
diagnosis, *601
of diabetic rats on atherogenic diet, 75-80
and glucose intolerance, *672
in glucose tolerance survey, 171
and portal cirrhosis, 776

MYOINOSITOL
metabolism, and galactose toxicity, *820

N

NECROBIOSIS LIPOIDICA DIABETICORUM, *358

NEGROES
glucose-6-phosphate dehydrogenase deficiency and glucose tolerance, *208

NEPHRECTOMY
and glucose uptake study, *741-742

NEPHROPATHY
and insulin clearance, 265

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70
February, 71-140
March, 141-210
April, 211-282
May, 283-368
June, 369-442
July, 443-544
August, 545-614
September, 615-680
October, 681-752
November, 753-824
December, 825-896

NERVOUS SYSTEM
and diabetic anhydrosis, *277
and fatty acid metabolism and ketogenesis, 259-263
and hypoglycemia, *674
and lipolysis
and substrate regulation, 576-588
sciatic nerve
sorbitol pathway, *509
vagus nerve
and insulin secretion, 443-448, 852-856

NEUROPATHY, DIABETIC, *66
and anhidrosis, *277
and bladder dysfunction, 331-334
and microangiopathy, 189
pathology, *279
and Valsalva maneuver, 462-465

NITROGEN
excretion
and glucose production, *507-508
and insulin, 18-20
retention, *887

NOREPINEPHRINE
and diabetogenic effect of alloxan, 130-131
and hypoglycemia, *435
lipolytic effects, 584

NORETHYNODREL
and diabetes, *675

NUTRITION
and canned food diet, 461
and carbohydrate absorption, *742
and copper deficiency, 851-874
and corn oil, 627
and diabetes mellitus, 738
and iron absorption, 651
in Lapland children, 318
and leaf proteins, 721, 733
and linoleic acid, 492, 501
and liver vitamin A, 704
and "moldy" peanut meal, 646
and protein-vitamin concentrates from petroleum, 795
and vitamin E, 376
and yams, 575

O

OBESITY
in age and tolbutamide response study, 163-164
and diabetes, *206, 600, *744, 862
in Pima Indians, *520
and diabetes diagnosis, *601
and fatty acid synthesis, *817
and free fatty acid changes during glucose tolerance tests, 179
and high caloric diet, *137
and hyperglycemia, *673
and insulin activity, *819
and insulin, *891
metabolism, 484-485
and insulin response, 145, 468-470
to glucagon, 666-669
and lipid metabolism, *509
and lipoprotein lipase activity
and dextran sulfate, 239-241
and phenformin and ethanol, *508
and pregnancy
and plasma insulin levels, *278
and starvation, *275
and thyroid autoimmunity and diabetes, *531

OCTANOATE
and insulin release, *892
and protein synthesis, 756-758

OCTOPAMINE, 273

ORAL CONTRACEPTIVES
and carbohydrate metabolism, *361, *440, 590-594
and glucose tolerance, *136, *440, *603
and plasma insulin and blood glucose, *137

ORAL HYPOGLYCEMIC AGENTS. *See also* Sulfonylureas
acteohexamide, 118-126
and "chemical" diabetes, *526
compared, *204
and diabetic pregnancy, 60-61
and dose errors, 884
and mortality, *603

OSTEOPATHY
and diabetes, *438-439

OXYGEN
consumption
and thyroid gland, *889

OXYTOCIN
and glucose uptake, 31

P

PALMITATE
metabolism
and acetate, 202

H-3-PALMITATE
and triglyceride metabolism in alloxan diabetes, 90-95

PANCREAS
and antiglucagon, *65
beta cells, 800-803
and alloxan, 242-249, *815
degranulation, and hyperglycemia and hypoglycemia, 493-499
in diabetes, *533-534
and glucose, glucagon and tolbutamide, *892
granulation, and glucose, 839-845, 846-851
of infants of diabetic mothers, 306
structure and function, 674
blood diversion study, *675
carcinoma
glucagon-secreting, *135
of diabetic and nondiabetic rats, 74
insulin
from diabetic and nondiabetic sources, 687-693
in insulin distribution study, 405-407
and prediabetes, 615-619
in late pregnancy, *890-891
and vagus nerves, 852-856
insulin secretion, *602
and octanoate, *892
islets
adenoma, *436
and diabetes, *672
of hyperglycemic mice, 21-24
lesions in rats, 108-110
in spontaneous diabetes, *513-514
and stimulated mitotic activity, *516
stimulation, *514
in streptozotocin-induced diabetes in rats, 52-55
tumors, 409-413
isolated perfused dog
and insulin biosynthesis, 647-650
mouse
and alloxan study, 83-88
orthotopic allotransplantation of, *357
perfusion, 449-450
rat
insulin release, 381-384, 449-453, *511
and isolation of intact islets of Langerhans, 35-38
vasoconstriction
and suppression of diabetogenic effect, 130-131

PANCREATECTOMY
clinical and metabolic response, *360
and dental changes, 805
and fatty metabolism and ketogenesis after liver denervation, 259-263
and glucose tolerance
and extracellular fluid insulin, *511-512, 551-556
and hypoglycemia, *438
and insulin effect on nitrogen excretion, 18-20
partial
and hypercholesterolemia, *538
and synalbumin, 389-391

PANCREATITIS
and hyperglucagonemia, *439

PANCREOZYMIN, *527-528
and insulin secretion study, 141-144

PENTOLINIUM, 584-585

PEPTIDES
and insulin, *277
and insulin I-131 degradation, 29-30

PERIODONTAL DISEASE
and diabetes, 336-339

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70
February, 71-140
March, 141-210
April, 211-282
May, 283-368
June, 369-442
July, 443-544
August, 545-614
September, 615-680
October, 681-752
November, 753-824
December, 825-896

PERTUSSIS SENSITIZATION, *513

PHENETHYLBIGUANIDE
mechanism of action in normals, 302-304

PHENFORMIN
absorption and metabolism, *741
and diabetes, *529, *820
and obesity, *601
and ethanol
in obesity, *508
metabolism
in rat adipose tissue, 869-873
and weight reduction, *534

PHENFORMIN HYDROCHLORIDE
and diabetes, *206
and obesity, 600

PHENINDIONE
and tolbutamide, 213

PHENIPRAZINE, 273

PHENOTHIAZINE, 710
and diabetes diagnosis, 725-726
and T-wave malformations, 726

PHENTOLAMINE
and vagal stimulation, 447-448

PHENYLBUTAZONE
and tolbutamide, 211

PHENYLETHANOLAMINE-N-METHYL
transferase, *529

PHENYLKETONURIA
and amino acid disorders, *356

PHENYLTHIOUREA TASTE SENSITIVITY
and glaucoma, 20, 25, 324

PHOSPHATE
and experimental dental caries, 340

PHOSPHOGLUCOISOMERASE
and lactate dehydrogenase, 21

PHOSPHOGLYCERIC KINASE, 22

PHOSPHOLIPIDS
in pancreatectomized-sympathectomized dogs, 262

PHOSPHORYLASE
in glycogen storage disease, *67

PHYSIATRIST
and diabetic management, *66, *67

PIMA INDIANS
and obesity and diabetes, *520

PITUITARY GLAND
ablation
and diabetic kidney, 636-642
and diabetic retinopathy, 1, *519-520, *815
growth hormone
and RNA, *203
and growth hormone deficiency, 478-481
and insulin inhibition, *523
necrosis, *506-507
stalk section
and hyponatremia, *524
and retinopathy, *532

PLACENTA
and insulin and alloxan diabetes, 227-231
insulin transfer, *528-529
lactogen
in hypopituitary patients, *206

PLASMA
acid-ethanol extracts, 290
and diet, *819
amino nitrogen
and cortisol, *817
catecholamine
and glucagon, *357
corticoids
and blood glucose, *532
free fatty acids
and arginine, 480-481
and carbohydrate metabolism, 765-774
and glycerol, *358
glucagon, *747-748
glucose
and amino acid and diet, *358
and diazoxide, *748
free fatty acids, ketone and ovine-growth hormones, *201-202
and growth hormones, *207
and lipolysis, 576-588
nonesterified fatty acid, glycerol, insulin, and diabetes onset, *890
growth hormones
and diabetic instability, *504
and fasting and glucose loading, *66
and hypoglycemia, *675
and hypoglycemic agents, *524
and hypokalemia, 314
and latent diabetes, *137
insulin, 418
and cortisol, 566-570
and glucocorticoids, *204
and glucose, corticosteroid and tolbutamide, *136
and growth hormone, *603
and oral contraceptives, *137, 590-594
and pituitary hormones, *359
and pregnancy, *278
prolonged elevation, *513
response, 466-471, *813
and tolbutamide, *745
and vagal stimulation, *444
and vagotomy, *444
and xylitol, *439
insulin-like activity
and low-protein diet study, 98
and oral and intravenous glucose loading, 141
lipids
and ethanol, 39
uptake, *889
lipoprotein lipase
and dextran sulfate, 239-241
and protein and carbohydrate loads, *522-523
proteins
and adrenocorticotropin, *207
radioimmunoassay of A-chain, 685
tolbutamide
and dicoumarol, 211-212
triglycerides
and insulin, *889-890
and mestranol, *525
turnover time, *440
zinc, *602

POMPE'S DISEASE, *67

PORPHYRIA CUTANEA TARDA, *358

POTASSIUM
and carbohydrate metabolism, 312-317
and chronic uremia, *510
deficiency
and glucose tolerance and insulin response, *510
dietary
and malnutrition therapy, 149, 155
glucose uptake, *361
and insulin release, 377
loading
and hypertensive diabetics, *360

PREDIABETES, *65
classification, 540
diagnosis, 348
and glucose tolerance tests, 14
and insulin response, 560
to hyperglycemia, 560-565
pathogenesis, 615
and periodontal changes and dental caries, 804-809
and pregnancy, *133-134
and serum insulin response, *535-536
and siblings of diabetic children, 159-160
and synalbumin insulin antagonism, *279
and triamcinolone tests, 57-60
and vascular disease, 831-834

PREDNISOLONE
and glomerular lesions, 51

PREDNISONE
-glycosuria test, *202
and hypoglycemia, *135
and plasma immunoreactive insulin, *514
and retinopathy, *529-530

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70	May, 283-368	September, 615-680
February, 71-140	June, 369-442	October, 681-752
March, 141-210	July, 443-544	November, 753-824
April, 211-282	August, 545-614	December, 825-896

PREGNANCY. *See also* Pregnancy, diabetic
and chronic renal disease, *67
and diabetes diagnosis, *601
and fetal-maternal insulin, *516-517
and glucose loading, *359-360
and glucose tolerance, *202
and low-protein diet, 96-106
and glucose tolerance tests, *360
and insulin sources, *359
and pancreas insulin, *890-891
and plasma insulin levels, *278
and serum insulin activity, *436
and urine glucose, *747

PREGNANCY, DIABETIC
and blood glucose, *359
and chlorpropamide, 60-61
and insulin levels, *819
management, *137
obstetric data, *356
and pituitary necrosis, *506-507
and placental changes, 227-231
and plasma and glucose study of infants, *439-440
and serum insulin activity, *436
and tolbutamide, *522

PROBENECID
and serum lipids, *204, *748

PROLACTIN
and glucose uptake, 31-32
and hypopituitary children, *202
and muscle permeability to 3-methylglucose, 28-29

PROPRANOLOL
and hypoglycemia, *435, *438

PROSTAGLANDIN
and hyperglycemia, *515
metabolic effects, *202

PROTEINS
-aggravated hypoglycemia
and sulfonylureas, *519
and glucose tolerance, *355
and growth hormone activity, *207
and hyperglycemia, 232-236
and insulin-like activity, 427-428
leaf, 721, 733
and methylprednisolone, *520
from petroleum, 795
release
and lipolytic hormones and insulin, *67
and soya milk, 376
synthesis
and free fatty acids and insulin, 753-763
and insulin, 20

PUROMYCIN
and insulin release, *815

PYELONEPHRITIS
and urine, 334

PYRIDOXINE
deficiency
and amino acid disorders, *356

PYRUVATE
and gluconeogenesis, *522
and hydrazine, *276
and insulin release, 377
metabolism
and alcohol, 784-790
and oral contraceptives, *361

PYRUVIC ACID-PHENYLHDRAZONE
and hyperglycemia, *355

PYRUVIC KINASE, 22

R

RACE
and diabetes, 191
and fatty acids of adipose tissue, *674

RADIOAUTOGRAPHY
of alloxan-diabetic mice pancreases, 84, 86-87

REFSUM'S SYNDROME, *205

RETINA
and diabetes, 828-829
new vessels in plane of, 5-6

RETINOPATHY, DIABETIC, *137
and arterial fluorescein studies, 1-10
and cryohypophysectomy, *519
and hyponatremia, *524
and hypophysectomy, *538-539
and insulin, 264
and intraocular pressure, *355, *890
photographic grading, *816
and pituitary ablation, *519-520, *815
and pituitary stalk section, *532
and prednisone, *529-530
prognosis, 728-732

RIBOSE
and insulin secretion, *511, *744

RNA
metabolism
and transplanted tumor study, *207
polymerase
and growth hormone, *203

S

SALICYLATES
and insulin, *515

SARCOSINEMIA
and amino acid disorders, *356

SCHIZOPHRENIA
and T-wave malformations, 726

SECRETIN, *527
and insulin secretion, *435
and tolbutamide, *887

SERUM
albumin
and malnutrition, 96
antibodies
and insulin immunity study, 403
anti-insulin
assay, *207
and glucose and ketone production, *507
and glucose metabolism, 472-477
and insulin-like activity study, 693
cholesterol
and cardiovascular lesions, 71-81
and corn oil diet, 627
and diabetes, 862
and dietary carbohydrate, *134-135
and lipoprotein lipase activity, 239-240
cholesterol and triglyceride
and phenformin hydrochloride, *206
citrate
and lipid metabolism, *509
free fatty acids
and triglycerides, 797-799
free fatty acids and ketones
and fat-loading and heparin, *275
glucagon
and starvation, *517
glucose
and chlorpropamide, 487-491
of diabetic and nondiabetic rats on atherogenic diet, 73
and lipodystrophy, 717-718
β-glucuronidase
and alloxan diabetes, *134
immunoreactive insulin
and glucose infusions, 145-148
half-life, *538
and prediabetes, *535
insulin
and arginine, 268-269
and diabetes, *743
and glucagon and epinephrine, *436
glycogenosis type I, 791-794
in insulin distribution study, 405-407
and methylprednisolone, *520
in offspring of one juvenile-diabetic parent, *524
in pregnancy, *436
insulin, growth hormone and hydrocortisone
and abdominal surgery, *136
insulin-like activity
and prediabetes, *512, 621
lactate
and hyperuricemia, *276
lipids, 717
and fructose and glucose, *204
and premature coronary disease, *537
and probenecid, *748
and sucrose, *279

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70	May, 283-368	September, 615-680
February, 71-140	June, 369-442	October, 681-752
March, 141-210	July, 443-544	November, 753-824
April, 211-282	August, 545-614	December, 825-896

phosphates
in diabetes, *201
phospholipids
and atherogenic diet, 73
potassium
and hypokalemia study, 313-314
proteins
and insulin-like activity, 483
triglycerides
and lipoprotein lipase, *136
reduction
and diet, *134
uric acid
and diabetes, 862-867

SEX
and arginine, 268, 270-271
and caloric intake study, 34
and diabetes
and cancer, *521
and diabetic syndrome, *744
and fatty acids of adipose tissue, *674
and glucose tolerance, 13
in hyperglycemia study, 233
and influence of fructose and glucose on serum lipid levels, *304
and insulin response, 469
and liver vitamin A, 704
and spontaneous lesions in rats, 108-110
and substrate regulation in fasting, 576, 578
and vascular disease, 826

SHEEHAN'S SYNDROME, *506-507
and retinopathy, 731

SHOCK
hypoglycemic
and oral sodium, *539

SHOCK THERAPY
and glucose tolerance tests, 723

SITOSTEROL
and corn oil diet, 627

SKIN
capillaries
and juvenile diabetes, *675
color
and diabetes, *437
and diabetes
and cancer, *521
disorders
and diabetes, *358
-fold thickness
and glucose uptake, *436
and linoleic acid, 492, 501
and microangiopathy study, *748

SODIUM BICARBONATE
and metabolic acidosis, *135

SODIUM LACTATE
and metabolic acidosis, *135

SODIUM TOLBUTAMIDE TEST, *435
and hypoglycemic shock, *539

SODIUM WARFARIN, *136

SORBITOL PATHWAY, *509

SOUTH AFRICAN BANTUS
diabetes and vascular disease study, *279

SOUTH AFRICANS
study of ultrastructure of dermal capillaries, 191-196

SPLEEN
in insulin distribution study, 405-407

SPLENOMEGALY
and high-fat diet, 74

SQUIRREL MONKEY
carbohydrate metabolism impairment, 395-401

STARVATION
and glucose-6-phosphate dehydrogenase, *275
and glucose tolerance, 96, *742
and growth hormone secretion, *359
and nonsuppressible insulin-like activity, *536
and renal gluconeogenesis, *507
and serum glucagon and insulin, *517

STEATORRHEA
and diabetes, 455-460
and disaccharidase deficiency, 482, 486
and vitamin E, 376

STREPTOMYCIN, 370

STREPTOZOTOCIN
and diabetes, *512-513
-induced diabetes in rats, 51-60

STRESS
emotional
and blood glucose levels, *537
and insulin resistance, *536
and growth-hormone release, *439
and insulin response, *672

SUCROSE
dietary
and glucose tolerance, *134
and serum cholesterol, *134-135
ingestion
and serum lipids, *279

SUGAR
absorption
and amino acids, *135
and insulin secretion, *744
intake
and diabetes, 62-63
metabolizable
and insulin release, 377-384
penetration into muscle
and insulin, 26-32
tolerance
and high sugar diet, *888

N_1-SULFANILYL-N_2-BUTYLCARBAMIDE
and metabolism, *355

SULFAPHENAZOLE
and tolbutamide, 211

SULFONYLUREAS
acetohexamide, 118-126
and beta cell function, *206
and children, *436
and diabetic obesity, *601
and diabetic pregnancy, 60-61
-induced hypoglycemia, *601
and protein-aggravated reactive hypoglycemia, *519
and thyroid function, *887

SURGERY
abdominal
and glucose tolerance, serum insulin, growth hormone and hydrocortisone, *136
amputation, *815
management, *136-137
gastrectomy
and carbohydrate intolerance, *67
and insulin response, *672
islet-cell lesion removal, 598-599
pituitary ablation, 636-642, *815
pituitary stalk section, *532
transplantation of pancreas, *357
vagotomy
and glucose-mediated insulin release, 446
and plasma insulin and blood glucose, 444
and vascular disease, *67

SYNALBUMIN INSULIN ANTAGONIST, *527
and B-chain albumin, *890
and diabetes, *279
failure in vivo, 386-393
during glucose-tolerance tests, *674
and heredity, 615
and insulin-like activity, 426-427

T

TEETH
caries
and phosphate, 340
periodontal disease
and diabetes detection, 336-339
and prediabetes, 804-809

TEMPERATURE
and insulin output, 371-372

TES-TAPE, 83

TESTES
in insulin distribution study, 405-407

TESTOSTERONE
and alloxan-diabetes, *741

THALIDOMIDE, *360

THEOPHYLLINE
and insulin release, 451-452

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70	May, 283-368	September, 615-680
February, 71-140	June, 369-442	October, 681-752
March, 141-210	July, 443-544	November, 753-824
April, 211-282	August, 545-614	December, 825-896

THIAZIDE
-induced diabetes
and triglyceride ingestion, *134

THYROID
autoimmunity
and diabetes and obesity, *531
function
and adipose tissue metabolism, *889
and insulin secretion, 643-645
in malnutrition, 155
and sulfonylurea, *887
and infant malnutrition, 335
insulin
in insulin distribution study, 405-407

THYROTOXICOSIS
and diabetes diagnosis, *601
and growth hormone, *275

TISSUES
adipose
and anti-insulin serum and glucose metabolism, 472-473
and carbohydrate metabolism and insulin responsiveness, *65-66
carbon flow, *888
and chloroquine, *886
fatty acid and composition, *674
and free fatty acid release, 175-180
glucose-U-C-14 conversion to fatty acids, 777-783
and hydrogen ion production, *440
and insulin, *890
and insulin and insulin-like activity assays, *67
and insulin-like activity, *358
and insulin-response, *359
and lipolysis, *889
lipoprotein lipase activity, *136
metabolism, *889
metabolism in alloxan-diabetic and fasted-refed rats, *204
and nervous system, 259-263
and phenformin, 869-873
and stimulation of glucose metabolism, *137
basement membrane, *818
brain
glucose uptake, *437
epididymal fat pad
and insulin-like activity assay, 695-702
epiphysial tibial cartilage
and hormone assays, *133
frog sartorius muscle
and insulin, 26-32
gastrointestinal
glucagon immunoassay, *137
glucose uptake, *435-436
in insulin distribution study, 403-404
mammalian
insulin content, *516
pancreatic
and diabetes, 687-693
rat diaphragm
and free fatty acids and insulin, 753-763
and insulin antagonism, 386
and insulin assay, *204
rat epididymal and adipose
and glucose uptake and caffeine, *355
rat fad pad
and biguanides, *818
and insulin assays, 418
rat hemidiaphragms
and glucose uptake, 30

TOLAZAMIDE
-induced hypoglycemia, 352-353

TOLBUTAMIDE
and anticoagulant therapy, *136
beta-cytotropic effects, *892
and carbohydrate metabolism impairment, 398-401
and diabetes, *744
and diabetic amyotrophy, 181, 182
and diabetic pregnancy, *522
and dicoumarol, 211-214
and growth hormone, *886-887
and insulin secretion, *360, 377-384, *511
and juvenile diabetes, 215-218
and lipoatrophic diabetes, 708
nine-year study, *201
and phenindione, 213
and plasma insulin, *745
and plasma insulin, glucose and corticosteroids, *136
and pregnancy, 307
response
and age, 161-169
and glucocorticoids, *204
and glucose tolerance in cardiovascular disease, 15-17
and secretin
and serum insulin, *887
tests
and squirrel monkeys, 396-397
tolerance tests
and childhood hypoglycemia, *816
and weight reduction, *534

TOXOCARA CANIS INFESTATION, 100, 105

TRANSPLANTATION
renal, *439
of tumor, 409-410

TRANYLCYPROMINE
and alloxan-diabetes, 810-811

TRIAMCINOLONE
provocative test
in children of diabetic parents, 57-60

TRIGLYCERIDE
and ethanol ingestion, 39
and growth hormones, *358
and lipoprotein lipase, *136
long-chain and medium chain
and glucose tolerance, 796-803
and low sucrose diet, *279
medium chain
and ketosis, *134
metabolism
and alloxan-diabetic rats, 90-95
response
and diet, *436-437

TRYPTOPHAN
metabolites
and glucose uptake, *892

TULAREMIA
and insulin response, 369-375

TUMORS
beta cell
ultrastructure studies, 800-803
growth-hormone-secreting
transplantation of, *207
insulin-producing
and hypoglycemia management, *136
islet cell
and alloxan, 88
histology and histochemistry, 409-413
and insulin content and metabolism, 415-417
removal, 598-599
pheochromocytoma
and insulin secretion, *207

TWINS
and diabetes, 41, 157, 159, 346
and immunoreactive insulin and glucose, *526
and insulin response to glucose, *813
monozygotic
and insulin response, 616, 618, 622-623

TYROSINEMIA
and amino acid disorders, *356

U

ULCER
neurotrophic and secondary to vascular disease, *66

UNITED STATES
diabetes prevalence, *746

UREA
formation
and growth hormone, *358
nitrogen
and growth hormone, *202

UREMIA
chronic
and potassium, *510
and glucose and insulin metabolism, *886
and insulin, *742

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70	May, 283-368	September, 615-680
February, 71-140	June, 369-442	October, 681-752
March, 141-210	July, 443-544	November, 753-824
April, 211-282	August, 545-614	December, 825-896

URINE
acetohexamide excretion, 122, 125-126
citrate
and lipid metabolism, *509
corticosteroids
and low-protein diet study, 100-101
glucose
and pregnancy, *747
glucose and acetone
in alloxan diabetic mice, 83, 84
insulin
assay, *891-892
in insulin distribution study, 405-407
in normals, *747
ketones
and hyperglycinemia, *135-136
phosphates
in diabetes, *201
radioactivity
in insulin distribution study, 404
in renal papillary necrosis, 664-665
residual
in diabetes, 334
steroid excretion rates, *507
sugar
and blood sugar, 503
determination by the two-drop Clinitest method, 557-559
and electric shock stress, 321
tests
and diabetic rats on atherogenic diet, 72
and sugar intake, 62
zinc excretion, *601

V

VAGUS NERVE
and insulin secretion, 443-448, 852-856

VALSALVA MANEUVER
and diabetes, 462-465

VASCULAR DISEASE
and diabetes, 825-837, *889
and diabetic neuropathy, *279
and glucose tolerance, 171-174
of lower extremities
physiatrist's management, *67
peripheral
and foot lesions, *815
prevention, 834-837
in South African Bantu diabetics, *279
and ulcers, *66

VITAMINS
A
and insulin, 704-707
in canned food, 461
D, 376
from petroleum, 795

W

WEIGHT. *See also* Obesity
in age and tolbutamide response study, 163-164
and arginine response, 268, 270-271
and calorie intake study, 34
change
in hyperglycemia study, 233
of diabetic and nondiabetic rats, 72
gain
in glucose tolerance study, 13
and growth hormone therapy in malnutrition, 148, 155
and linoleic acid, 492
and liver vitamin A, 705
loss
and phenformin, *206
and oral contraceptives, 594
and plasma insulin response, 468-470
reduction
and diabetes, *534

WERNER'S SYNDROME, *358

X

XANTHOMA DIABETICORUM, *358

XYLITOL
and insulin response, *439

D-XYLOSE TEST, *458, *742

Z

ZINC GLUCAGON
and amino acids, *517-518
and hypoglycemia, *135, *136

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70	May, 283-368	September, 615-680
February, 71-140	June, 369-442	October, 681-752
March, 141-210	July, 443-544	November, 753-824
April, 211-282	August, 545-614	December, 825-896

AUTHOR INDEX 1967

In this index are the names of authors of articles that have appeared in DIABETES and those whose articles have been abstracted in the Journal during 1967. Entries marked with an asterisk (*) indicate authors of material that appeared in the ABSTRACTS only. The Subject Index appears on page 1.

A

Aarseth, S., *355
Abrams, M. E., 219-226, *435-436
Abramson, Eugene A., *435, *508, *601
Aceto, Thomas, Jr., *673
Ackerman, Eugene, *504, *535
Adams, Constance J., 319-324, 325-330
Adams, Donald A., *519
Adams, Levi C., *745
Adesman, J., *510
Ahrén, K., *275
Ailabouni, H., *133
Alburn, Harvey E., *203, *523
Alexander, D., *133
Alfrey, Allen C., *886
Allen, David T., *201
Allison, S. P., *672
Almary, F., *601-602
Altilia, F., *361
Amiri, S., *891
Ammon, J., *202-203
Anderson, E., *820
Anderson, James W., *519
Anderson, John, *206, *275, *355
Andersson, Bertil, *813
Andrew, M., *277
Angervall, Lennart, *741, *748
Antoniades, Harry N., *886
Aoki, Teruaki, *517
Appleman, M. Michael, *133
Arimura, Akira, *439
Arison, R. N., 51-56
Arky, Ronald A., *435, *508, *601
Armaly, Monsour F., *741, *886
Arvill, A., *275
Ascoli, Nino, *67
Ashcroft, George, 272-274
Ashkar, Edmundo, 259-263
Ashmore, J., *507
Astrug, A. Kh., *201

B

Bach, H. G., *747
von Baeyer, H., *747
Bagdade, John D., *672
Bagolou, Paul J., *741
Bahn, Robert C., *892
Bailey, Rita, 377-385
Baker, Lester, *438, *504-505
Ball, Eric G., *889
Balodimos, Marios C., *133-134, *201, *435, *519-520
Balodimos, Peli M., *435
Balogh, Miriam, *134-135
Barbezat, G. O., *742
Barboriak, Joseph J., 141-144
Bartelt, K. M., *891
Bartley, J. C., *275
Bartsch, Glenn E., *674
Basford, R. E., *816
Bassett, J. M., *134, *201-202, *207, 566-571
Batchelor, E. L., 62-63
Batchelor, Robert Bruce, 418-434
Baumeister, F., *360
Baumgold, Deborah, *440
Bauung, Hermann, *275
Beaser, Samuel B., *435, *601
Bechmann, William H., *203, *523
Beck, Paul, *886
Becker, Bernard, *355
Becker, Kenneth L., *516
Beckmann, Rüdiger, *741
Beisel, William R., 369-376
Beizer, Lawrence H., *135
Bell, Fred, *744
Bell, S. M., *601
Belle, Ross de, 215-218
Belleau, Roger, *435
Belmonte, Mimi M., 215-218, 557-559
Beloff-Chain, Anne, 472-474
Benedetti, Andrea, *206, 666-669
Benjamin, Fred, *360
Bennett, Leslie L., *509-510
Bennett, Peter H., *520
Benoit, Frederick L., *886
Benson, Bryant, *741
Berant, Moshe, *438
Berg, K., *355
Bergen, Stanley S., Jr., *275
Berker, Ferhan, *602-603
Berkowitz, Donald, *65
Berman, Louis, *438
Berne, C., 21-25
Best, Charles H., 132
Bethencourt, Anthony V., *202
Bierman, Edwin L., *672
Bilic, Nedjeljko, *741-742, *746-747
Bilis, A., *202
Birk, Sharon A., *359, 590-594
Björntorp, P., *136, *742
Black, A. L., *275
Blackard, William G., 681-686, 852-857
Blackwell, W. L., 395-401
Bleicher, Sheldon J., 312-318, *510
Blizzard, Robert M., *202, *206
Bloodworth, J. M.B., Jr., 181-190
Blum, Andrea S., 268-271
Blumenthal, Herman T., 402-408, *531
Boden, Guenther, *886-887
Böhle, E., *202-203
Bohonos, N., *357
Bolinger, Robert E., *204, *529-530
Bonechi, I., 455-461
Bongiovanni, Alfred M., *603
Bonomi, U., *355
Bookman, John J., *522
Boorujy, Samuel R., 336-340
Borgatti, E., *361
Borghelli, Ricardo F., 804-809
Borondy, Maria, *820
Böttcher, M., *818
Bottermann, P., *435, *887
Bowie, M. D., *742
Bowles, W. H., 704-707
Bowyer, Denis, *536
Boyns, D. R., *527
Bracchetti, D., *361
Braun, Alan P., *65
Braunsteiner, H., *440
Bray, George A., *889
Breckenridge, A., *435
Bresnick, George, *355
Bret, J., 589-599
Bretz, Gedeon, *887
Brewer, George J., *202
Breuer, Charles B., *203
Brien, T., *276
Briese, Franklin W., 40-50
Briggs, J. D., *742
Britton, H. G., *133
Brodoff, Bernard N., *358, *531, *742
Brody, Jerome I., *135
Brolin, S. E., 21-25
Bromer, William W., *517-518
Brooks, Aldrich M., Jr., *744
Brown, David F., 90-95
Brown, G. A., *887
Browning, E., *507

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70
February, 71-140
March, 141-210
April, 211-282
May, 283-368
June, 369-442
July, 443-544
August, 545-614
September, 615-680
October, 681-752
November, 753-824
December, 825-896

Buchan, Douglas J., *602
Buchanan, Keith D., 466-471, *517, *518, *742, *887
Buckle, Richard M., *206
Bunnag, Sirotma, 83-89
Bunnag, Srichitra C., 83-89
Bunnell, Ivan L., *505
Burch, Thomas A., *520
Burday, S. Zane, *506-507
Burgess, John A., *275, 478-482, *603
Bürgi, H., *66
Burke, Gerald, *887
Burkeholder, James N., 11-14, 150-160
Burton, Stanley D., *510
Buschiazzo, Hector O., 810-811
Buschiazzo, Perla Mordujovich de, 810-811
Buse, John, 753-764
Buse, Maria G., 753-764
Butler, L., *742-743
Butterfield, W. J. H., 219-226, *435-436
Byron, John, 656-665

C

Cahill, George F. Jr., *67, *743
Caird, F. I., 502-503
Camerini-Dávalos, Rafael A., *65, *201, *526, *527-528
Campbell, G. D., 62-63
Campbell, James, *276, *436, *520
Caramia, Felice, *745
Cardus, D., *534-535
Carlson, Karen L., *137, *359, 590-594
Carlström, Sven, *887
Carpenter, Anna-Mary, 493-501, *672
Carpenter, Frederick H., *206-207
Carrasco-Formiguera, R., 130-132
Carrington, Elsie R., *436
Carson, Paul E., *203
Cassaro, J. A., 51-56
Castillo, Enrique J. Del, 259-263
Catanzaro, R., 472-474
Caulfield, James B., 227-231
Cerasi, Erol, 615-627, *813
Cerri, B., 455-461
Chain, E. B., 472-477
Challoner, David R., 545-550
Chamberlain, M. J., *672, *887
Chance, Ronald E., *517-518
Chao, Kuen-Lan, *531
Chen, Edith T., 319-324, 326-330
Chenoweth, M., *889
Chevrette, Line, *355
Chiba, Mamoru, *525-526
Chlouverakis, C., *888
Christ, O., *890
Ciaccio, E. I., 51-56
Cibis, Andrea, *355
Clark, Charles M., Jr., *516-517
Clarke, B. F., *66
Cline, J. H., *358
Coates, J. H., *203
Cocchiara, John C., 852-857
Cochran, Burt, Jr., *748
Codoceo, Rosa, *439
Coffey, John D., Jr., *672
Cohane, Jak, *525
Cohen, A. M., *134-135, *355, *888
Cohen, N., *527
Cole, Harold S., *526
Coleman, D. L., *672
Colle, Eleanor, 215-218
Collens, William S., *521
Colwell, John A., *505, 560-565
Colwell, R. W., *205
Conn, Jerome W., *356, *510-511, *512
Constam, G. R., *601-602
Conway, F. James, *533
Conway, Martin J., 576-589
Cooper, Alan J., 272-274
Copinschi, Georges, 268-271
Cornblath, Marvin, 306-311, *440, *531-532
Cornwall, Gail, *888-889
Corsini, G., 455-461
Cortazar, Jaime, *521
Cowan, J. S., *507-508
Cox, B. D., 219-226
Coyle, Virginia, 882-885
Coyne, Robert V., *136
Craig, James W., *533, 708-714
Creutzfeldt, W., *277, *355-356, *817-818
Cristofori, Fred C., *509
Croughs, R. J. M., *745
Culp, H. W., 118-127
Curtis, Gretchen, *674

D

D'Addabo, A., *813-814
Dahlqvist, Arne, *672-673
D'Alonzo, Anthony C., *603, *891
Dandrow, Robert V., *356
Daniel, P. M., *888
Danowski, T. S., 600
Datey, K. K., *743
Daughaday, William H., *886
Daunas, J., *358, *531
Davidson, I. W. F., 395-401
Davidson, J. K., *526-527
Davidson, Mayer B., 386-394, 576-589
Davidson, Paul C., *521-522
Davies, D. M., *601
Davis, Charles B., *435
Davis, Mary Beth, *888
Deckert, T., 728-733
DeGowin, Richard L., *203
De Moor, P., *888
Denton, R. M., *65, *888
DeRuyter, H. A., *745
DeVilliers, Darrell C., Jr., *743
Devlin, James G., *276
Devoto, Francisco C. H., 804-809
Devrim, Sevim, *377-385, *436
Dietzman, Ronald H., *357
Di Girolamo, M., *65-66
Dikstein, S., *133
Dill, I. K., *357
Ditschuneit, H., *202-203
Ditzel, Jørn, 264-267
Dixit, Padmakar K., *509, *743
Doar, J. W. H., *361, *440
Döbert, E., *202-203
Dobkin, Gerald B., *521
Dobson, Harold L., *522, *534-535, *888-889
Dohrmann, R. E., *134
Dolger, Henry, *522
Dollery, C. T., 1-10, *435
Donaldson, Charles L., 268-271
Donnell, George N., *276
Dorfman, R. I., *205
Dougherty, Jocelyn, *66
Douglas, C. P., 60-61
Dow, Jocelyn, *135
Drash, Allan L., *202, *436, *527
Dray, Jan, 487-492
Drenick, Ernst J., *819
Dublin, T. D., 858-868
Dulin, William E., *512-513, *524-525, *527, *672, *673, *745-746
Duncan, L. J. P., *66, 628-635, 636-642, 664-666
Dunn, A., *889
Dyck, D. R., *276

E

Eberlein, Walter R., *603
Economou, Peter G., 171-174
Egan, Thomas J., *278
Ehrentheil, Otto F., 319-324, 325-330
Eisenstein, Albert B., *522
Eisentraut, Anna Marie, *137, 283-288, *517
Ekka, E., *278
Ellenberg, Max, *66, 331-335
Ellis, E. V., *892
Engelberg, H., *134
Ensinck, John W., 289-301, *536, 545-550
Eppes, R. Bennett, *203
Epstein, F. H., *512
Epstein, Murray, 181-190
Erausquin, Jorge, 804-809
Erickson, Marcia, *674
Ernesti, M., *515
Estrich, David L., 232-237, *505-506, *522-523
Etzwiler, Donnell, 111-117
Eu, R., *819
Ezdinli, Ediz Z., 443-448

F

Fagerberg, Sven-Erik, *742, *748
Fain, John N., *743
Fajans, Stefan S., *356, *510-511
Falsetti, Herman L., *505
Faludi, G., 175-180
Fanfani, G., *813-814
Farquhar, John W., *436-437
Fatourechi, Vahab, *504, *535
Feinberg, Arthur W., *889
Fenichel, Richard L., *203, *523
Field, James B., *528
Field, Richard A., 227-231. *745
Figueroa, William G., *819
Fine, Richard N., *276

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70
February, 71-140
March, 141-210
April, 211-282
May, 283-368
June, 369-442
July, 443-544
August, 545-614
September, 615-680
October, 681-752
November, 753-824
December, 825-896

Finestone, Albert J., 336-340
Fischer, Edmond H., *133
Fischer, Joseph N., *889
Fisher, Donald D., 734-737
Fisher, Gail F., *746
Flanagan, C. Larkin, *203
Florin, James R., *203
Floyd, John C., Jr., 356, *510-511
Foa, Piero P., 409-414, *535
Foglia, Virgilio G., 804-809
Folstein, Marshal F., *523-524
Forbes, Audrey E., *440
Forell, M. M., *435
Forsham, Peter H., *206, 268-271, 666-669
Förster, Harald, *357
Fortney, Sidney R., *276, *743-744
Frank, Arthur, *436-437
Fraser, G. R., *205
Fraser, T. Russell, *435, *436-437, *746, *747, *815, *816, *891-892
Frasier, S. Douglas, *437
Freinkel, Norbert, *205-206, *508
Frerichs, H., *277
Frethem, Allen A., *524
Freund, Gerhard, *134
Friedman, Gerald J., *66
Friedman, A. I., *205
Froesch, E. R., *66, *277
Frohman, Lawrence A., 443-448, *673
Fukayama, George, 232-237, *522-523
Fukuda, Kouhei, *277
Furey, Warren, *505
Furth, Jacob, *207
Futterweit, Walter, *748

G

Gabbay, Kenneth H., *509
Gabel, Paul V., *359-360
Gagliardino, Juan J., *277
Gagnon, Henry, *744
Gaitan-Yanguas, Mario, *521
Gale, Morna, *279
Galli, Maria Elisa, 259-263
Galloway, J. A., 118-127
Galton, David J., *889
Gandolfi, E., 455-461
Garcia, M. J., *524
Gaskin, Joe H., *358
Gasparo, M. de, *819
Gastineau, Clifford F., *524, *532-533
Gatti, Richard A., *437
Geefhuysen, J., *277
Geminiani, G. D., *361
Gepts, W., *814
Gerber, R., *277
Gerrard, John W., *602
Gerritsen, George C., *512-513, *524-525, *672, *673, *745-746
Gershberg, Herbert, *135, *525
Gerstenfeld, Jacob, *205
Gilgore, S., *515-516
Giovanniello, Thomas J., 319-324, 325-330
Gitelson, Simon, *437
Gleason, R. E., *524, *526, *538, *814
Glick, Aaron, *202
Glick, Seymour M., *437
Gliemann, Jorgen, *814
Glitzer, M. S., 51-56
Glover, J. S., *601
Gocke, H., 438-439
Goetz, Frederick C., *509, *511, *744
Gold, Ernest M., *519
Goldberg, M., *510
Goldberg, M. D., 62-63
Gomez-Acebo, J., *890-891
Gonet, Alain E., *746
Gooch, W. M., *889
Goodkin, George, *525
Goodman, H. Maurice, *356
Goodman, J. I., *277
Goodner, Charles J., 386-394, 576-589
Gordon, Harry H., *360
Goto, Yoshio, *525-526
Gottlieb, M. S., *526
Gottstein, U., *437
Graber, Alan L., 145-149
Grácia, Pedro M., 127-130
Greenberg, Beryl Z., *744
Greene, David G., *505
Greenwood, F. C., *675
Greep, Jacobus, *745
Gries, F. Arnold, *889-890
Grillo, T. Adesanya I., 409-414
Grinnell, Edward H., *744
Grodsky, Gerold M., *206, *509-510, 666-669
Groen, J. J., *134-135, 858-868
Gross, Richard C., *436-437
Grumbach, M. M., *816
Gubner, Richard S., *525
Guggenheim, Wolf, *526
Gulbenkian, A., *513
Gundersen, Kare, *539, *744
Guthrie, Richard A., *530
Gwinup, Grant, 715-721, *748

H

Hackel, Donald B., *814-815
Haft, David E., *515
Hagenfeldt, Lars, 15-17
Hahn, Inge, *820
Hajdu, Andrew, 108-110
Hales, C. N., *357-358, *890
Hamilton, James P., *438
Hammarström, Lars, *815
Hamwi, G. J., *537
Hanley, T., *744
Hansen, J. D. L., *742
Hansen, J. Molholm, 211-214
Haque, Nasir, *504-505
Hardigg, Jack B., 734-737
Harlan, William, *675
Harper, P. V., *439
Harpur, Eleanor R., 557-559
Hartroft, W. Stanley, 71-82, *538
Hashim, Sami A., 796-799
Haslam, R. M., *746
Haslbeck, Gertrude, *357
Hauer, J., 598-599
Hausler, H. R., *276
Hazlett, B. E., *526-527
Heard, C. R. C., 96-107
Held, K., *437
Helge, Hans, *358-359
Hellman, Bo, *673, *815
Henderson, J. R., *888
Heptner, W., *890
Herczeg, B., *507
Herman, J. B., 858-868
Herman, Robert H., *519
Hernandez, Rodolfo E., 810-811
Herrera, M. G., *511-512, 551-556
Hesselsjö, R., *741
Hetenyi, G., Jr., *507-508
Heuser, Gunnar, *519
Heyns, W., *888
Hidalgo, Francisco Dietzman, *357
Hill, D. W., *815, *816
Hill, G. J., *511-512, 551-556
Hilton, James G., *275
Hindmarsh, J. T., *135
Hird, Hazel J., *207
Hirohata, Tomio, 875-881
Hiroshi, Abe, 238-241
Ho, Irwin P., 40-50
Hodson, W. Alan, *674
Hoerner, M. Tischer, *815
Hoet, J. J., *278, *819
Hogan, Michael D., *820, *892
Hogan, Richard A., 289-301
Holcomb, George N., *527
Hollifield, Guy, *275, *355, *358
Holmes, Joseph H., *886
Holmlund, C. E., *357
Hood, B., *136, *275
Horemans, B., *278
Horino, Masaharu, 402-408
Horton, Edward S., *814-815
Hoshi, Mituru, *137, 238-241
Houssay, Bernardo A., 259-263
Houston, E. S., *602
Howorth, P. J. N., *675
Hsia, David Yi-Yung, *356, *437
Hsu, Jen-Sie, *207
Hug, George, 791-795
Hulse, Mildred, *525
Hummel, Katharine, P., *672
Hunter, W. M., *66
Hurxthal, Lewis M., *133-134
Hutchinson, C. F., 777-783

I

Ingemanson, Carl-Axel, *887
Ingle, Dwight J., 18-20
Insull, William, Jr., *674
Ireland, J. T., 628-635, 636-642
Irvine, R. O. H., *135
Ishida, Tadashi, *510
Ito, Mitsuo, *66

J

Jackson, Robert L., *530
Jahnke, Karl, *889
Jain, I. S., *890
Jakob, A., *66, *277

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70	May, 283-368	September, 615-680
February, 71-140	June, 369-442	October, 681-752
March, 141-210	July, 443-544	November, 753-824
April, 211-282	August, 545-614	December, 825-896

Jakoi, Laszlo, *742
Jangaard, N. O., *515-516, 869-874
Jansen, G. R., 777-783
Jarrett, R. J., *527, *528, *891
Javid, Rouhollah, 443-448
Javier, Zenaida, *135, *525
Jeanrenaud, Bernard, *744
Jeffrey, P. D., *203
Jenkins, Melvin E., *202
Jervell, J., *674, *890
Jimenez, Jose A., *527-528
Joassin, Guy, 306-311
Joel, Cliff D., *137
Johnson, B. Connor, *748
Johnson, Philip C., *888
Johnston, Ivan D. A., *136
Joliff, James W., 708-714
Jones, E. E., *743, *745
Jonsson, Anders, *507
Jonsson, K. A., *275
Jönsson, Lars-Erik, *203-204
Joplin, G. F., *815, *816
Jørgensen, Kai R., *439-440
Joshi, Prakash C., *435

K

Kaden, Melvin, *528
Kadish, Arnold Henry, *528
Kagan, Avir, *437
Kahana, David, *438
Kalser, M. H., *360
Kanazawa, Yasunori, *439
Kang, M., *137
Kaplan, S. L., *816
Karam, John H., *206
Katsoyannis, Panayotis G., *277
Katsuki, Shibanosuke, *66
Kaye, Robert, *438, *504-505
Kearns, Thomas P., *524
Keen, H., *527, *528, *891
Kekki, Matti, *358
Kenny, Frederic M., *438
Kern, Horst, *516
Kessler, Jacques, *137
Ketterer, Hermann, *137, 283-288
Kikuchi, Jin, *525-526
Kilby, D., *135
Kilo, Charles, *135, 377-385
Kim, J. N., *528-529
Kim, Minjern, 238-241
Kimmel, Joe R., 687-694
Kingsbury, K. J., *277-278
Kinney, Thomas D., *814-815
Kinsell, Laurance, 232-237, *505-506, *522-523
Kipnis, David M., *204, *516
Kirkman, Hadley, 409-414
Kitabchi, Abbas E., *529
Klayman, Joel, *205
Klimt, Christian R., 40-50
Klink, D. D., *438
Kneubuhler, Hans A., 141-144
Klopfenstein, T. J., *358
Klusmann, H., *357
Kneer, P., *355-356, *817-818
Knight, G. J., *744
Knobloch, Hilda, *674
Knopf, Ralph F., *356, *510-511
Knowles, Harvey C., Jr., *438, 670
Kobernick, Sidney D., 409-414
Köhler, M., *134
Kohner, Eva M., 1-10, *205, *815, *816
Kolker, Allan E., *355
Koop, C. Everett, *438
Kornhauser, David, *201
Kosaka, Kinori, *439
Kostianovsky, Mery, 35-39
Kotler, Morris N., *438
Krebs, Edwin G., *133
Kreisberg, Robert A., 784-790
Kristensen, M., 211-214
Kryston, Leonard J., *506, *529
Kuhlencordt, F., *438-439
Kuksis, A., *507-508
Kumaresan, Perianna, *356-357
Kusakcioglu, Oznur, *435
Kuschke, H. J., *357
Kuzuya, Takeshi, *439
Kyner, Joseph L., *529-530
Kvo, J. F., *357

L

Labat, Joseph A., 852-857
Labhart, A., *66
Lacey, A. H., 198-200
Lacy, Paul E., 35-39, *674-675
Lambert, André E., *278, *818-819
Lamdin, E., *816
Landau, Bernard R., *817
Lang, C. M., 395-401
La Placa, Gerald, 341-345
Largiader, Felix, *357
Lascelles, R. G., *279
Laurance, Bernard M., *744
Lauris, V., *743, *814
Lawecki, J., *891
Lawson, D. H., *279
Lazarow, Arnold M., 493-501, *509, *672, *743, 839-845, 846-851
Lazarus, Sydney S., 242-251
Lax, Henry, *889
Lebovitz, Harold E., *814-815
Leeman, W., *601-602
Lefebvre, Pierre J., 415-417
Lein, Allen, 560-565
Leite, C. A., *360
Lemberg, A., *358
Lenhoff, Miguel, 352-353
Levin, Marvin E., *135
Levine, R., *358, *531, *742
Lewis, J. G., *744
Like, A. A., *744-745, *815
Lillehei, Richard C., *357
Lin, Boniface J., *744
Linde, B., 21-25
Lindsay, Richard W., *358
Lines, J. G., *887
Lippman, Heinz I., *66
Lisker, Sheldon H., *135
Lochner, Amanda, 252-258, *439
Logothetopoulos, John, *516
Long, C. N. H., *817
Long, J. K., *512
Lopez-Mondragon, R., *514
Lopez-Quijada, C., *890-891
Lowy, C., *747, *891-892
Lubos, Manuel C., *602
Lucas, C. P., *512
Luft, Rolf, 615-627, *813
Luke, R. G., *742
Lukens, F. D. W., *536
Lund, G. H., *512-513
Lundevall, J., *355
Lundquist, Ingmar, *747
Luse, Sarah A., *745
Luthra, C. L., *890
Luyckx, Alfred S., 415-417
Lyngsøe, Jens, *745
Lyons, Gary W., *357

M

Macdonald, J., *204
MacGillivray, Margaret H., *673
MacIntyre, A., *601
Macintyre, Neil, *603
MacLeod, Robert M., *67
MacMahon, Brian, 875-881
McCraw, Edward F., 643-646
McDonald, Glen W., *746
McGavran, Malcolm H., *135
McGurl, Thomas J., *603
McKay, Eric, *359
McKay, Marguerite, 839-845
McKiddie, M. T., 466-471, *742, *887
McMahon, R. E., 118-127
McNamara, James V., *203
McRae, Wayne, *744
McWilliams, Nancy B., *436
Madison, Leonard L., 252-258, *439, *507, *536, 765-776
Magid, Gail A., *524
Mahan, Clare M., *530-531
Mahler, Richard J., *513
Maingay, D., *745
Malaisse, Willy J., *207, *513-514, *602, 643-646, *745-746
Malaisse-Lagae, Francine, *513-514, *602, 643-646, *745-746
Maney, John W., *511, *744
Manfield, Pauline, *438
Mansford, K. R. L., 475-477
Marble, Alexander, *201, *519-520, 825-838
Marglin, A., *278
Marks, Vincent, *675, *747-748
Marshall, F. J., 118-127
Martin, Dan A., *820, 882-885, *892
Martin, Julio M., 71-82, *277, *538, *892
Marx, Ruth Nunamaker, 839-845
Mason, John W., *136
Matos, Otsenre E., *202
Matsui, Nobuo, *357
Mauer, A. M., *887
Mdalel, Jose, *888-889
Meade, Robert C., 141-144
Medalie, J. H., 858-868
Meek, Joseph C., *204, *529-530

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70
February, 71-140
March, 141-210
April, 211-282
May, 283-368
June, 369-442
July, 443-544
August, 545-614
September, 615-680
October, 681-752
November, 753-824
December, 825-896

Megyesi, Clara, *747-748
Mehnert, Hellmut, *357
Mehra, S. K., *601
Meinert, Curtis L., 40-50, *534
Melani, F., *891
Melanik, Ghodsi, *67
Menkes, John H., *135-136
Merimee, Thomas J., *275, 478-482, *530, *603
Merrifield, R. B., *278
Messina, Edward J., 595-597
Metz, Robert, 341-345
Meyer, Urs A., *204
Michaels, George, *505-506
Mikat, Eileen, *814-815
Miki, Eishi, *67, *744, *815
Millar, E. Joan, *601
Miller, Max, *520
Miller, Ralph E., *136
Mills, Lewis C., *506, *529
Mills, S. C., *134
Milner, R. D. G., *357-358
Mintz, A. A., *889
Mirsky, Stanley, *206, *748
Mitchell, M. L., *515, 656-663
Molnar, George D., *504, *535
Moltz, Arnold, *137
Mondon, Carl E., *510
Money, W. L., *207
Moorhouse, J. A., *276, *602
Morgan, Carl R., 734-737
Morin, Lawrence J., 664-666
Moser, Karen, *748
Moshagen, D., *355-356, *817-818
Mount, F. W., 858-868
Moxness, Karen E., *504
Müller, Eugenio, *439
Muller, Sigfrid A., *358
Murthy, Yoga N., *530
Muscogiuri, A., *813-814
Mustala, O. O., *204

N

Nakamura, H., 175-180
Nakamura, Koji, 238-241
Nakamura, Mitsuo, *816
Nanda, N. C., *743
Narahara, H. T., 26-34, *361, *514
Nathanielsz, P. W., 462-465
Navarrete, Victoriano N., 57-60, 127-130
Nechemias, Charles, *522
Nelson, J. K., *530
Nelson, Norman C., 852-857
Nemechek, Kitty, *509-510
Nestel, P. J., *204
Neufeld, N. H., 858-868
Nibbe, Albert F., *892
Nice, Marvin, 341-345
Niemeyer, Herman, *439
Nikkilä, Esko A., *358
Nilsson, S., *741
Nishikawara, Margaret T., *278
Nixon, C., *513
Nixon, D. A., *133
Nora, J. J., *889

O

Oakley, Nigel W., 1-10, *528, *746, *815, *816
Oaks, Merrill C., *355
O'Brien, Donough, 572-575
O'Brien, John P., *439
O'Connor, Sheilah M., *440
O'Connor, Thomas P., *534
Odem, D. Dwight, *888-889
Odifreddi, M. T., *361
Ohneda, A., *517
Oji, N., *137, *816
Oken, Donald E., *67
Onsberg, Trold, *744
Orci, Lelio, *746
Ortman, Patricia, *748
Oski, Frank A., *603
Östenson, Stig, *747
Osterman, Juraj, *746-747
Ostrander, L. D., *512
O'Sullivan, John B., *356, *530-531
Otto, Hellmut, *675
Owen, John A., Jr., *355, *358
Özand, P., *891
Özen, Muhlis A., *602-603

P

Paloyan, Daniel, *439
Paloyan, Edward, *439
Palva, I. P., *204
Parker, Mary L., 306-311, *519, *531-532
Passey, R. F., *820
Paterson, J. W., 1-10
Patnaik, B. K., 628-635, 636-642
Paul, E. M., *507-508
Paul, T. N., *67
Paulsen, Elsa P., *205
Pavel, I., *278
Pedersen, Jørgen, *439-440
Pedersen, L. Mølsted, *439-440
Pek, S., *510-511
Pelkonen, Risto, *358
Pell, Sidney, *603, *891
Penhos, Juan C., *358, *531, *742
Pereira, J. N., *515-516, 869-874
Pereira, Virgilio Concalves, 302-305
Pérez, Norma, *439
Perley, Michael, *204
Perlstein, Irving B., *531
Persson, B., *136
Peterson, Michael J., *523-524
Peterson, William F., *136
Pfaff, Kenneth J., *535
Pfeiffer, E. F., *891
Pickens, James M., 11-14, 156-160
Pictet, Raymond, *746
Pieptea, R., *278
Pildes, Rosita S., 306-311, *440, *531-532
Pinson, E. Rex, *515-516, 869-874
Plager, John E., *357
Poffenbarger, Phillip L., 289-301
Pokrajac, Niksa, *741-742, *746-747
Polk, Hiram C., *135
Pollack, Albert A., *603
Pollock, H. G., 687-694
Polomis, V., 598-599
Pomerance, William, *440, *603
Pontén, Jan, *203-204
Pooler, Karen, *815
Popowitz, Leonard, *67
Porte, Daniel, Jr., 150-156, *672, *675
Posner, Norman Ames, *440, *603
Potthoff, Siegfried, *889
Poucher, Russell L., *136, *360, *748
Poulsen, J. E., 728-733
Powell, Elinor D. U., 227-231
Powell, Gerald F., *202
Powell, Richard C., *523-524
Powell, Robin D., *203
Power, Lawrence, 483-486
Pozefsky, Thomas, 161-171
Poznanski, W. J., *532
Preeyasombat, Chawalit, *438
Premachandra, B. N., *531
Probst, G. W., *205
Prowse, K., *672
Pruss, M. P., 51-56
Purser, D. B., *358

Q

Quabbe, Hans-Jürgen, *358-359
Quan-Ma, Ronald, *278
Quesada, E. M., *534-535

R

Raben, M. S., *515
Rabinowitz, D., 478-482, *530, *603
Raiti, Salvatore, *202
Rama, Prema B., *205
Rand, Robert, *519
Randle, Philip J., *65, *278-279, *888
Rappaport, A. M., *507-508
Rasio, E. A., *511-512, 551-556
Rastogi, G. K., *202
Rastogi, Krishna Sudha, *276, *436, *520
Ravnik, Anthony, 232-237
R.-Candela, J. L., *890-891
Reaven, Gerald M., *436-437, 487-492
Recant, Lillian, *135, 377-385, *436
Reder, Jason A., *675
Redisch, Walter, 595-597
Reed, Nora, *743
Rees, Searle B., *519-520
Reid, R. L., *134
Reinskou, T., *355
Reissert, Klaus, *275
Reitz, Roger P., *529-530
Renold, Albert E., *746, *818-819
Renschler, H. E., *747
Rerup, Claus, *747
Reyna, Leo J., 319-324, 325-330
Richards, R., 60-61
Rietti, Ciro T., 259-263
Rifkind, B. M., *279
Riggs, L., *603
Rihan, Z., *891
Rimoin, David L., 346-351
Rishi, Surendra, *516

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70
February, 71-140
March, 141-210
April, 211-282
May, 283-368
June, 369-442
July, 443-544
August, 545-614
September, 615-680
October, 681-752
November, 753-824
December, 825-896

Riss, E., 858-868
Riviera, Irene R., 127-130
Robbins, Leonard, *888-889
Roberts, Doris E., 882-885
Roberts, H. J., *532
Robertson, Patrick D., *67
Rodbell, Martin, *67
Rodriguez, Ricardo R., 810-811
Roldan, Alicia, 259-263
Romney, Seymour L., *359-360
Rona, George, 108-110
Root, Allen W., *603
Root, Howard F., *526, 875-881
Rooth, Gösta, *747
Rose, F. Clifford, *205
Rosenbloom, Arlan L., *205
Rosevear, John W., *504, *535
Ross, E. J., 462-465
Ross, H., *136
Roth, Henry, *136
Roth, Nathan, *519
Rouiller, Charles, *746
Roy, Claude C., 572-575
Rubenstein, Arthur H., 191-197, *438, *747, *891-892
Rucker, C. Wilbur, *532-533
Rudas, Barbara, *275
Rudman, Daniel, *359, *440
Rull, Juan A., 352-353, *356
Rupp, J. J., *538-539
Russek, Allen S., *136-137
Russell, George, *359
Ryan, Will G., 171-174, *514, *892

S

Saccoman, Frank M., 839-845
Safir, Aran, *205
Saha, J., *514
Sailer, S., *440
St. John, D. J. B., *435-436
Saito, Takashige, *439
Salomon, Mardoqueo I., *205
Salter, D. N., *601
Samaan, Naguib A., *533
Samols, Ellis, *675, *747-748
Sanbar, Shafeek S., *533, *748, *892
Sanchez-Medina, Mario, *521
Sandalci, Özkan, *602-603
Sanders, Robert B., *359
Sanders, Tommy J., *360
Sandhofer, F., *440
Sandler, Richard, *205-206, *508
Saperstein, Richard, *743
Sarkozy, Eva, 557-559
Sässoon, H. F., *748
Sáve-Söderbergh, Johan, *748
Schaefer, Louis E., *206
Schaefer, L. D., *889
Schalch, Don S., *506-507, *533-534
Schally, Andrew V., *439
Scherstén, Tore, *742
Schilling, Erich, *358-359
Schlierf, Guenter, 232-237
Schmidt, Philip, 312-318
Schmidt-Nielsen, Knut, *814-815
Schnatz, J. David, *505, *534
Schobert, L., *513
Scholkens, B., *357
Schotland, M. G., *816
Schrier, Stanley L., *203
Schubert, William K., 791-795
Schulte, William J., 141-144
Schultz, Robert B., *206, *436
Schwartz, Gerald P., *816
Schwartz, K., *887
Schwartz, M. Jay, *206, *748
Schwartz, M. Stephen, 595-597
Schwartz, Michael, 264-267
Schwartz, Robert, *201
Schwartz, Theodore B., 171-174, *514, *534, *892
Schwarz, K., *435
Schweisthal, Michael R., 839-845
Scott, F. B., *534-535
Seftel, Harold C., 191-197, *279
Segal, Stanton, *136
Seidensticker, J. F., *537
Service, Frederick J., *504, *535
Sevier, B. R., 647-651
Seyffert, Willis A., Jr., 765-776
Shackney, Stanley E., *137
Shambaugh, George E., III, 369-376
Shank, Paul W., *359, *440
Shapcott, Dennis, 572-575
Sharma, D. C., *205
Sharpe, Alton R., Jr., *439
Shaw, Ralph A., *506, *529
Sheldon, Joanna, *206
Shepherd, B. P., *601
Sherard, Earl S., Jr., *674
Sherman, Frank E., *278
Sherman, Lawrence, *205
Shigeta, Yukio, *137, 238-241
Shima, Kenji, *535
Shipp, Joseph C., *202
Shirai, Takeshi, *816
Shiu Yeh Yu, 402-408
Shnaider, Jose, 302-305
Shochat, Gina, *137
Shor, Velvl P., 127-130
Shreeve, W. W., *816
Shuman, John, 483-486
Sidbury, J. B., Jr., *675
Silverstein, Gerald E., *887
Silverstein, Murray N., *892
Silverstone, Felix A., *440, *603
Silverstone, J. Trevor, *206
Simon, E., *277
Simonsen, Sv. E., 728-733
Simpson, Ronald G., *206, 666-669
Sims, Ethan A. H., *816, *817
Singer, Nechama, *603
Singhal, Radhey L., *207
Siperstein, Marvin D., *505-506
Sirek, Anna, *817
Sirek, O. V., *817
Skillman, Thomas G., *744
Skutella, E., *355-356, *817-818
Slavinski, R., *816
Slobin, Lawrence I., *206-207
Smet, Guido, *533
Smith, Beverly R., *275
Smith, B. W., *819
Smith, Desmond F., *509-510
Smith, Elizabeth K., *675
Smith, Fred G., Jr., *437
Smith, O. K., *817
Smith, R. Lawrence, *67
Smithen, C. S., *602
Smrcka, J., 598-599
Sodero, E., *531
Sodoyez, Jean C., 415-417
Soeldner, J. Stuart, *516-517, *538, 551-556, *743, *814, *815, 886-887
Söling, H. D., *817-818
Solomon, Solomon S., *529, *536, 545-550
Sonenberg, M., *207
Soricelli, R. R., *538-539
Sorkin, Allen I., *887
Sosa, Humberto, *536
Sotos, Juan F., *674
Souvatzoglou, A., *435, *887
Sparks, Lowell L., 268-271
Spaulding, John S., *202
Spellacy, William N., *137, *359, 590-594
Spergel, Gabriel, 312-318, *510
Spiro, Robert G., *818
Spitzer, J. J., 175-180
Stahleber, H., *435
Stauffacher, Werner, *818-819
Steel, Maxwell W., Jr., *136
Steele, J. Murray, 595-597
Stein, Jay H., *360
Steinberg, Terry, 715-721, *748
Steinke, Jurgen, *67, *743, *815, *890
Stephenson, N., *276
Stern, Alan, 312-318
Stimmler L., 652-655, *887
Stjernholm, Melvin, *511
Stouffer, John E., *207
Strauss, José, *276
Sturchio, Edward A., *67
Sullivan, John B., *509
Sulman, F. G., *133
Sussman, Karl E., 449-454, *511, *537, *675, *886
Svien, Hendrik J., *524, *532-533
Swendseid, Marian E., *819
Swerdloff, Ronald S., 161-171
Szabo, Olga, *513

T

Tabachnick, I. I. A., *513
Takaku, Isao, *525-526
Takeda, Yoshihiko, *359-360
Tantibhedhyangkul, Phienvit, 796-799
Tarlov, Alvin R., *203
Taylor, Keith W., *206
Teitelbaum, Alisa, *134, *355
Templeton, Bryce, *536
Terry, Erwin N., 595-597
Themann, Hermann, *675
Thier, Samuel, *136
Thiffault, C. A., *510-511
Thomas, K., *819
Thomas, P. K., *279
Thorell, Jan, *203-204
Tisell, L. E., *741
Tobin, Jordan D., 161-171

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70
February, 71-140
March, 141-210
April, 211-282
May, 283-368
June, 369-442
July, 443-544
August, 545-614
September, 615-680
October, 681-752
November, 753-824
December, 825-896

Tokalti, M., *891
Toker, Cyril, 800-803
Tometsko, Andrew M., *277
Torres, Isabel H., 57-60, 127-130
Touber, J. L., *745
Toussaint, D., *814
Toyota, Takayoshi, *525-526
Tulgan, Henry, *675
Turner, C. W., *356-357
Turner, M. R., 96-107
Turtle, J. R., *207
Tustison, Winston A., 576-589
Tyler, Jean, *747-748
Tzagournis, M., *537

U

Ullberg, Sven, *815
Unger, Roger H., *135, *283-288, *517
Urgoiti, Enrique J., 259-263

V

Vahouny, George V., *819
Vallance-Owen J., *279, *360-361, *674, *890,
Valverde, I., *517
Van Itallie, Theodore B., *275, 796-799
Vance, James E., *517, *518
Vandenbergh, Richard I., *537
Varandani, P. T., *820
Vaughan, Gary D., 449-454, *511
Vecchio, Danièle, *818-819
Vecchio, Thomas J., *136
Velasco, Mutya San Agustin, *360
Vinnick, Leonard, *508
Vinyard, Elizabeth, *819
Volk, Bruno W., 242-251
Vranic, M., 507-508

W

Waddell, William R., *675
Wagner, Horst, *675
Wahlberg, Fredrik, 15-17
Waitzkin, Leo, 722-727
Wajchenberg, Bernardo Leo, 302-305
Wakim, Khalil G., *892
Walker, A. R. P., *279
Wallace, A. L. C., *201-202, *207, 566-571
Warner, Nancy E., 83-89
Warren, W. D., *360
Waters, Hilda, *537-538
Watkins, Julia D., *820, 882-885, *892
Weber, George, *207
Weber, Herbert, 331-335
Wehe, Robert A., *674
Weinsier, Roland L., *134
Weisenfeld, Shirley, *537-538
Welborn, T. A., *136, *435, *747
Weldon, Virginia V., *202
Weller, John M., *820
Wellman, Klaus F., 242-251
Wells, Henry J., *278, *820
Wells, Lemen J., 839-845, 852-857
Wells, William W., *278, *820
Welsh, George W., 3rd, *816
Wesley, M. E., 26-34
Wesson, L. G., *538-539
West, C. E., *820
West, Kelly M., *360
Westberg, G., *275
Wheatley, I. S., *207
Wherry, Frances E., *136
Whichelow, M. J., 219-226, *435-436
White, P., *524
White, Randolph, *742
Whitney, J. E., 647-651
Whitty, Albert J., 409-414
Wieners, H., *438-439
Wigglesworth, A., 219-226
Wilansky, Douglas L., *137, *820
Wilber, J. F., *207
Wilcox, D. S., *360
Wilder, Joseph R., *67
Williams, R. F., *538
Williams, Robert H., 145-149, 289-301, *517, *518, *529, 545-550
Williams, T. Franklin, *820, 882-885, *892
Williamson, J. R., *507
Willms, B., *818
Wilson, F. A., *360
Wilson, J. S. P., *360-361
Wilson, Robert B., 71-82, *538
Wiseman, G., *135
Wisniewski, Konstanty, *515
Woeber, Kenneth A., *435
Wohltmann, Hulda J., 26-34, *361
Wolfe, Ava J., 695-703
Wolloch, Leon B., *525
Womack, Noel C., *672
Womack, William N., 11-14, 150-160, *530
Wood, Francis C., Jr., 145-149
Wrenshall, G. A., *507-508
Wright, A. D., *136, *746
Wright, Jackson, 664-666
Wright, Peter H., *207, *507, *513-514, *602, *745-746
Wu, C. H., *358, *531
Wulff, Johan, 252-258, *439
Wynn, Victor, *361, *440

Y

Yamada, Chisae, *819
Yamada, Kazuyori, *816
Yanoff, Myron, *137
Yaron, E., *134-135
Yerganian, George, *744
Yodaiken, Ralph E., 191-197
Yorke, R. E., *65
Young, E. C., 118-127

Z

Zahlten, R., *818
Zahnd, G. R., *277
Zak, Frederick G., *205
Zalme, E., *438
Zalut, Clyde, *277
Zampa, G. A., *361
Zanetti, M. E., 777-783
Zarebski, Maciej, *515
Zarowitz, Harold, *137
Zaske, Ruth, *511
Zervas, N. T., *538
Zeytinoglu, Ibrahim, *539
Zor, U., *133
Zweifler, Andrew J., *533

DIABETES: VOLUME 16 (1967) PAGE NUMBERS BY ISSUE

January, 1-70	May, 283-368	September, 615-680
February, 71-140	June, 369-442	October, 681-752
March, 141-210	July, 443-544	November, 753-824
April, 211-282	August, 545-614	December, 825-896